



(11) Publication number : **0 544 445 A2**

(12) **EUROPEAN PATENT APPLICATION**

(21) Application number : **92310544.9**

(22) Date of filing : **19.11.92**

(51) Int. Cl.<sup>5</sup> : **C07D 473/16, C07D 473/24, C07D 473/34, C07D 498/04, C07D 475/08, C07D 475/06, // A61K31/52, A61K31/525, A61K31/505, (C07D498/04, 263:00, 239:00)**

(30) Priority : **25.11.91 GB 9125001**

(43) Date of publication of application :  
**02.06.93 Bulletin 93/22**

(84) Designated Contracting States :  
**AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE**


(71) Applicant : **IMPERIAL CHEMICAL INDUSTRIES PLC**  
Imperial Chemical House, Millbank  
London SW1P 3JF (GB)

(72) Inventor : **Block, Michael Howard**  
**Alderley Park**  
**Macclesfield, Cheshire SK10 4TG (GB)**  
Inventor : **Harrison, Alison**  
**Alderley Park**  
**Macclesfield, Cheshire SK10 4TG (GB)**  
Inventor : **Hargreaves, Rodney Brian**  
**Alderley Park**  
**Macclesfield, Cheshire SK10 4TG (GB)**

(74) Representative : **Hay, Martin Alexander et al**  
**Group Patents Services Dept., PO Box 6, Shire Park, Bessemer Road**  
**Welwyn Garden City, Hertfordshire AL7 1HD (GB)**

(54) **Furyl-substituted purines, oxazoloypyrimidines and pteridines as adenosine antagonists.**

(57) **Compounds of formula I, and pharmaceutically acceptable salts thereof,**



in which R<sup>1</sup> is hydrogen (1-6C)alkyl or (1-4C)alkanoyl ;

A is -N=CQ-O-, N=CQ-NR<sup>8</sup>-, -N=CQ-CH=N- or -N=CH-CQ=N- ;

Q is 2-furyl ;

R<sup>8</sup> is hydrogen or C1-4C)alkyl ;

and R<sup>2</sup> has any of the meanings given in the specification, processes for preparing the compounds and pharmaceutical compositions containing them. The compounds are useful as adenosine antagonists.

This invention concerns heterocyclic compounds and, more particularly, certain furyl-substituted purines, oxazolopyrimidines and pteridines which have useful pharmacological properties (and in particular antagonise the actions of adenosine such as vasodilation). The invention also includes pharmaceutical compositions containing the heterocyclic compounds for use in treating certain diseases and disorders affecting mammalian cardiac, peripheral and/or cerebral vascular systems. Also included are processes for the manufacture and formulation of the heterocyclic compounds.

The compound theophylline (1,3-dimethylxanthine) has been used clinically (usually as its ethylene diamine salt, which is also known as aminophylline) as a respiratory stimulant, a centrally acting stimulant, a bronchodilator, a cardiac stimulant and as a diuretic. This diversity of clinical uses is an indication of the range of pharmacological actions which have been attributed to theophylline. These include phosphodiesterase inhibition, adenosine receptor antagonism, mobilisation of intracellular calcium and the release of catecholamines. Recently theophylline has also been reported to be useful in treating myocardial ischaemia (Maseri *et al.*, *The Lancet*, 1989, 683-686), skeletal muscle ischaemia (Picano *et al.*, *Angiology*, 1989, in press) and cerebral ischaemia (Skinhoj *et al.*, *Acta. Neurol. Scand.*, 1970, 46, 129-140). The beneficial effects of theophylline in these ischaemic disorders are believed to be due to a reduction or prevention of the phenomenon known as "vascular steal" by virtue of the compound's ability to antagonise the actions of adenosine by blocking the adenosine receptors which mediate metabolism-linked vasodilatation.

The "vascular steal" phenomenon can occur when the major artery supplying a particular vascular bed is partially or totally occluded resulting in ischaemia. In this situation, the compromised vascular bed dilates and blood flow is maintained by either an increase in flow across the narrowed vessel or by an increase in flow through the collateral vessels. However, increased metabolic activity in adjacent vascular beds results in release of mediators such as adenosine, causing them to dilate, resulting in the limited blood flow to the compromised vascular bed being "stolen" by these adjacent areas. The loss of blood from compromised to normally perfused vascular beds by the phenomenon of "vascular steal" further diminishes the blood flow in the compromised vascular bed.

The diversity of pharmacological properties possessed by theophylline make it difficult to use in the regular treatment or prevention of occlusive diseases and conditions of the vasculature. Thus, its associated action as a phosphodiesterase inhibitor results in cardiac stimulation which is deleterious for patients with myocardial ischaemia. Furthermore, the relatively low potency of theophylline means that dose-levels which are therapeutically useful are close to those which can cause serious central side-effects.

Several furyl-substituted purine and pteridine compounds are known. El Khadem, H.S. and Sindric, R., *Carbohydrate Research*, 34, (1974), 203-207 discloses 6-amino-8-(2-furyl)-1H-purine. This compound was obtained as a byproduct during the synthesis of certain 6-amino-8-hydroxyalkyl-1H-purines. The compound 2,4,7-triamino-6-(2-furyl)pteridine (also called furterene) is known as a diuretic.

We have now discovered (and this is a basis for our invention) that a group of furyl-substituted purines, oxazolopyrimidines and pteridines of formula I defined below are effective antagonists of the actions of adenosine and in particular of its vasodilatory actions.

According to the invention there is provided a compound of the formula I set out hereinafter (together with the other formulae appearing in Roman numerals) wherein:

R<sup>1</sup> is hydrogen, (1-6C)alkyl, or (1-4C)alkanoyl;

R<sup>2</sup> is hydrogen, cyano or a group of formula R<sup>3</sup>X;

R<sup>3</sup> (when not as hereinbelow defined together with X) is (3-12C)cycloalkyl, (3-6C)alkenyl, phenyl(3-6C)alkenyl, 5- or 6-membered heteroaryl, optionally substituted (1-6C)alkyl or optionally substituted phenyl,

said optionally substituted alkyl being unsubstituted or substituted by one of (3-6C)cycloalkyl, optionally substituted 5- or 6-membered heteroaryl, optionally substituted phenyl and a group of formula R<sup>4</sup>(CO)<sub>n</sub>X<sub>a</sub>(CO)<sub>m</sub> in which R<sup>4</sup> is (1-6C)alkyl, (3-6C)cycloalkyl, optionally substituted phenyl or optionally substituted phenyl(1-4C)alkyl, n and m are each 0 or 1 provided that n+m is 0 or 1, and that when m is 0, X and X<sub>a</sub> are separated by at least two carbon atoms, X<sub>a</sub> is oxy, thio, sulphonyl, sulphonyl or an imino group of formula -NR<sub>b</sub> in which R<sub>b</sub> is hydrogen, (1-6C)alkyl or together with R<sup>4</sup> and the adjacent nitrogen atom forms a 4 to 6-membered saturated heterocyclic ring,

said optionally substituted 5- or 6-membered heteroaryl being unsubstituted or substituted by 1 or 2 of (1-4C)alkyl, (1-4C)alkoxy and halogeno,

and any of said optionally substituted phenyl being unsubstituted or substituted by (1-4C)alkylenedioxy or by 1,2 or 3 of halogeno, cyano, trifluoromethyl, (1-4C)alkoxycarbonyl, hydroxy, hydroxymethyl, amino, (1-4C)alkanoylamino, (1-4C)alkoxymethyl, (1-4C)alkanoyloxy, benzyloxy, halogenobenzyloxy, (1-4C)alkylsulphonylamino,

(1-4C)haloalkylsulphonylamino, nitro, and (1-4C)alkyl or alkoxy optionally bearing a group of formula R<sup>5</sup>CO in which R<sup>5</sup> is (1-4C)alkoxy, (3-6C)alkylamino, (3-6C)cycloalkylamino or (N-(1-4C)alkyl) (N-(1-4C)dialkylamino(1-

4C)alkyl)amino, and sulphamoyl of formula  $-SO_2.NR^6R^7$  in which  $R^6$  and  $R^7$  are independently hydrogen or (1-4C)alkyl, or  $R^6$  is hydrogen and  $R^7$  is ((2-5C)alkoxycarbonyl)(CH<sub>2</sub>)<sub>q</sub>-, carbamoyl(CH<sub>2</sub>)<sub>q</sub> or (N-(1-4C)alkylcarbamoyl)(CH<sub>2</sub>)<sub>q</sub>, in which q is 0 or an integer of from 1 to 4, or  $R^6$  is (1-4C)alkyl and  $R^7$  is di(1-4C)alkylamino(1-4C)alkyl; and

- 5 X is a direct bond or oxy, thio, sulphinyl, sulphonyl or an imino group of formula  $-NRa-$  in which Ra is hydrogen, (1-6C)alkyl or together with  $R^3$  and the adjacent nitrogen atom forms a 4 to 6-membered saturated heterocyclic ring;

A is  $-N=CQ-O-$ ,  $-N=CQ-NR^8-$ ,  $-N=CQ-CH=N-$  or  $-N=CH-CQ=N-$ ;

Q is 2-furyl; and

- 10  $R^8$  is hydrogen or (1-4C)alkyl;

provided that when  $R^1$  and  $R^2$  are hydrogen and A is  $-N=CQ-NR^8-$ ,  $R^8$  is not hydrogen; or a pharmaceutically acceptable salt thereof.

- It will be appreciated that depending on the nature of the substituents, in containing one or more chiral centres, the formula I compounds may exist in and be isolated in one or more different enantiomeric or racemic forms (or a mixture thereof). It is to be understood that the invention includes any of such forms which possesses the property of antagonising the actions of adenosine, it being well known how to prepare individual enantiomeric forms, for example, by synthesis from appropriate chiral starting materials or by resolution of a racemic form. Similarly, the adenosine antagonist properties of a particular form may be readily evaluated, for example by use of one or more of the standard *in vitro* or *in vivo* screening tests detailed hereinbelow.

- 20 It will also be appreciated that the first nitrogen atom in the group A, reading from left to right, is attached to the pyrimidine ring para to the group R<sub>2</sub>.

A particular value for  $R^1$  when it is (1-6C)alkyl is, for example, methyl, ethyl, propyl or butyl, and when it is (1-4C)alkanoyl is, for example, formyl, acetyl or propionyl.

An example of a particularly preferred value for  $R^1$  is hydrogen.

- 25 A particular value for  $R^3$  when it is (3-12C)cycloalkyl is, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or norbornyl.

A particular value for  $R^3$  when it is (3-6C)alkenyl is allyl.

A particular value for  $R^3$  when it is phenyl(3-6C)alkenyl is 3-phenyl-2-trans-propenyl.

- 30 Particular values for  $R^3$  when it is 5- or 6-membered heteroaryl include, for example, pyridyl, isoxazolyl or thiadiazolyl.

Particular values for an alkyl group when  $R^3$  is optionally substituted (1-6C)alkyl are, for example, methyl, ethyl, isopropyl, propyl, butyl, *sec*-butyl and *n*-pentyl.

Particular values for optional substituents on alkyl when  $R^3$  is optionally substituted alkyl (such as methyl or ethyl) include, for example:

- 35 for (3-6C)cycloalkyl: cyclopropyl;

for optionally substituted 5- or 6-membered heteroaryl:

for the 5- or 6-membered heteroaryl: furyl, pyridyl or thienyl;

for the optional substituents:

for (1-4C)alkyl: methyl;

- 40 for (1-4C)alkoxy: methoxy; and

for halogeno: fluoro, chloro or bromo;

for a group of formula  $R^4(CO)_nXa(CO)_m$ ;

for  $R^4$ : methyl, ethyl, *n*-propyl, cyclohexyl, phenyl or 4-hydroxybenzyl,

for  $X_a$ : oxy, thio, NH, methylimino or,

- 45 together with  $R^4$ , piperidino.

It will be appreciated that when  $R^3$  represents the group  $R^4(CO)_mXa(CO)_n$ , n is 0 when Xa is  $-NR^b$ , and  $R^b$ , together with  $R^4$  and the adjacent nitrogen atom form a 4 to 6-membered saturated heterocyclic ring.

Particular values for optional substituents on an optionally substituted 5- or 6-membered heterocyclic ring include, for example:

- 50 for alkyl: methyl or ethyl;

for alkoxy: methoxy or ethoxy; and

for halogeno: fluoro, chloro or bromo.

Particular values for optional substituents on an optionally substituted phenyl (for example where  $R^3$  is optionally substituted phenyl or optionally substituted phenyl(1-6C)alkyl) include, for example:

- 55 for alkylenedioxy: methylenedioxy;

for halogeno: fluoro, chloro or bromo;

cyano;

trifluoromethyl;

- for alkoxycarbonyl: methoxycarbonyl;  
hydroxy;  
hydroxymethyl;  
amino;  
5 for (1-4C)alkanoylamino:acetamido  
for (1-4C)alkoxymethyl: methoxymethyl;  
for alkanoyloxy: pivaloyloxy;  
benzyloxy;  
for halogenobenzyloxy: 4-fluorobenzyloxy or 4-chlorobenzyloxy;  
10 for (1-4C)alkylsulphonylamino: methylsulphonylamino;  
for (1-4C)haloalkylsulphonylamino: trifluoromethylsulphonylamino;  
nitro;  
for (1-4C)alkyl or alkoxy optionally substituted by a group of formula  $R^5CO$ :  
for (1-4C)alkyl: methyl or ethyl;  
15 for (1-4C)alkoxy: methoxy or ethoxy;  
for  $R^5$ :  
for (1-4C)alkoxy: methoxy, ethoxy or t-butoxy;  
for (3-6C)alkylamino: n-propylamino;  
for (3-6C)cycloalkylamino: cyclopentylamino or cyclohexylamino;  
20 for (N-(1-4C)alkyl, N,N-(1-4C)dialkylamino(1-4C)alkylamino:  
(N-methyl, N,N-dimethylaminoethyl)amino;  
for sulphonyl of formula  $-SO_2NR^6R^7$ :  
for  $R^6$  and  $R^7$  are independently hydrogen or (1-4C)alkyl:  $-SO_2NH_2$  or  $-SO_2N(CH_3)_2$ ;  
for  $R^6$  is hydrogen and  $R^7$  is ((2-5C)alkoxycarbonyl)( $CH_2$ ) $_q$ , carbamoyl( $CH_2$ ) $_q$  or (N-(1-4C)alkylcarbamoyl)( $CH_2$ ) $_q$ ;  $R^7$  is methoxycarbonylmethyl, carbamoylmethyl or N-methylcarbamoylmethyl;  
25 for  $R^6$  is (1-4C)alkyl and  $R^7$  is di(1-4C)alkylamino(1-4C)alkyl:  $R^6$  is methyl and  $R^7$  is dimethylaminoethyl, dimethylaminopropyl or dimethylaminobutyl.  
One of the substituents on a substituted phenyl group is preferably in the para position.  
A particular value for  $R_a$  when it is (1-6C)alkyl is, for example, methyl or ethyl.  
30 Particular values for X include, for example, oxy, thio, NH, methylimino or, together with  $R^3$ , morpholino, thiomorpholino, pyrrolidino, piperidino or azetidino.  
Particular values for  $R^8$  include, for example hydrogen and methyl.  
A group of compounds of particular interest consists of those compounds of formula I wherein:  
 $R^1$  is hydrogen;  
35  $R^2$  is  $R^3X$   
 $R^3$  is (1-4C)alkyl, (3-6C)alkenyl, pyridyl(1-4C)alkyl or phenyl(1-4C)alkyl optionally substituted on the phenyl moiety by 1 or 2 of halogen, hydroxy, (1-4C)alkanoyloxy, (1-4C)alkyl and (1-4C)alkoxy;  
X is a direct bond, oxy, thio or NH;  
A is  $-N=CQ-O-$ ,  $-N=CQ-NR^8-$ ,  $-N=CQ-CH=N-$  or  $-N=CH-CQ=N-$ ;  
40 Q is 2-furyl; and  
 $R^8$  is hydrogen or methyl;  
and pharmaceutically acceptable salts thereof.  
Of this group of compounds, those wherein  $R^2$  is a 4-chlorobenzyl, 2-phenylethyl, 2-phenylethylamino, 2-(4-hydroxyphenyl)ethylamino, 2-(4-methylphenyl)ethylamino, 2-(4-methoxyphenyl)ethylamino or 2-(3,4-dimethoxyphenyl)ethylamino are especially preferred.  
45 Particular pharmaceutically acceptable salts include, for example, salts with acids affording physiologically acceptable anions, for example, salts with strong acids, such as hydrochloric, hydrobromic, sulphuric, phosphoric, methanesulphonic and trifluoroacetic acids. In addition, for those compounds of formula I which are sufficiently basic, suitable salts include, for example, salts with organic acids affording a physiologically acceptable anion such as salts with oxalic, citric or maleic acid. Certain compounds of formula I, for example those in which  $R^2$  comprises a phenol group, may form base salts with bases affording physiologically acceptable cations, such as alkali metal and alkaline earth metal salts.  
Specific compounds of the formula I which are of interest are described hereinafter in the accompanying examples, and the pharmaceutically acceptable acid-addition salts thereof, and these are provided as a further feature of the invention.  
55 The compounds of formula I may be manufactured using procedures analogous to those well known in the arts of heterocyclic and organic chemistry for the production of structurally analogous compounds. Such procedures are included as a further feature of the invention and include the following preferred procedures

for the manufacture of a compound of the formula I in which R<sup>1</sup>, R<sup>2</sup>, X, A and Q have any of the meanings defined above:

- 5 (a) A compound of formula II in which Z<sup>1</sup> is a suitable leaving group, for example halogeno (such as chloro or bromo) is reacted with a compound of formula R<sup>1</sup>NH<sub>2</sub>.

The process is conveniently effected at a temperature in the range of, for example, from 0 to 120°C. Suitable solvents for the process include alcohols such as ethanol or isopropanol, and ethers such as tetrahydrofuran. When R<sup>1</sup> is hydrogen, it is particularly convenient to employ a solution of ammonia in an alcohol, such as ethanol or isopropanol, at ambient temperature.

- 15 (b) Reacting a compound of formula III or a salt thereof with a compound of formula IV or a salt thereof, in which either R<sup>9</sup> is a leaving group (such as (1-4C) alkoxy, for example ethoxy) and X<sup>1</sup> is O or NH, or R<sup>9</sup> is CHO and X<sup>1</sup> is NH, and X<sup>2</sup> is O, S or NH.

The reaction may conveniently be performed in the presence of a solvent such as an alcohol (for example ethanol), a tertiary amine (for example pyridine) or a halogenated hydrocarbon, (for example chloroform). Preferably it is performed in the presence of a base, such as a tertiary amine (for example dimethylaminopyridine or pyridine). The temperature at which the reaction is performed is conveniently in the range of from 25 to 150 °C, for example from 60 to 100 °C.

When using fural-2-glyoxal as the compound of formula IV to prepare a compound of formula I in which A is -N=CH-CQ=N- or -N=CQ-CH=N-, the solvent conveniently comprises ethanol and water.

When a compound of formula I in which A is -N=CQ-CH=N- is desired, the reaction is preferably performed in the presence of an acid, for example a mineral acid such as sulphuric acid or hydrochloric acid.

- 25 (c) For the preparation of a compound of Formula I which A is -N=CQ-O- or -N=CQ-NR<sup>8</sup>, cyclising a compound of formula V in which one of R<sup>10</sup> and R<sup>11</sup> is hydrogen and the other is a group of formula C(=X<sup>4</sup>)Q in which X<sup>3</sup> is O or NH, and X<sup>4</sup> is O, S or NH.

30 The compound of formula V may conveniently be cyclised by treatment with a dehydrating agent, for example phosphorus pentoxide or phosphorus oxychloride. The cyclisation may be performed in the presence or absence of a solvent, conveniently at a temperature in the range of from 0 to 150 °C, for example from 50 to 120 °C.

- 35 (d) For the preparation of a compound of formula I in which A is -N=CQ-NR<sup>8</sup> and R<sup>8</sup> is (1-4C)alkyl, reacting a corresponding compound of formula I in which R<sup>8</sup> is hydrogen with an appropriate alkylating agent.

40 The alkylating agent may be a conventional alkylating agent such as a (1-4C)alkyl halide or di(1-4C)alkyl sulphate. The reaction is conveniently performed in the presence of a base, such as an alkali metal carbonate or hydroxide (for example, potassium carbonate). Suitable solvents for the reaction include amides (for example dimethylformamide), ethers (for example tetrahydrofuran) and alcohols (for example ethanol). The temperature at which the reaction is performed is conveniently in the range of from 0 to 100 °C.

- 45 (e) Reacting a compound of formula VI with an amidine of formula VII or, for a compound where R<sup>2</sup> is cyano, a cyanogen halide and an alkali metal cyanide.

The reaction may conveniently be performed in the presence of a solvent such as an amide (for example dimethylformamide), and at a temperature in the range of from 25 to 150 °C, for example from 60 to 120 °C. The reaction may conveniently be performed in the presence of a strong base, for example an alkali metal alkoxide such as potassium t-butoxide.

- 50 (f) For a compound of formula I in which X is O, S or NR<sub>a</sub>, reacting a compound of formula VIII in which Z<sup>2</sup> is a leaving group such as a (1-4C)alkylsulphonyl group (for example methylsulphonyl) with a compound of formula R<sup>3</sup>XH or a salt thereof.

The reaction may conveniently be performed in the presence of a solvent such as a nitrile (for example acetonitrile), an ether (for example t-butyl methyl ether, tetrahydrofuran or 1,2-dimethoxyethane) or an amide

(for example dimethylformamide), and at a temperature in the range of from 10 to 120 °C, for example from 30 to 80 °C. The reaction is preferably performed under basic conditions, which may be provided by the inherent basicity of the compound of formula R<sup>3</sup>XH or a salt thereof, or by a base such as a tertiary amine, for example pyridine or triethylamine, or an alkali metal alkoxide, for example sodium ethoxide.

5 It will be appreciated that those compounds in which R<sup>1</sup> is other than hydrogen may also be obtained by carrying out a conventional alkylation or acylation of the corresponding formula I compound in which R<sup>1</sup> is hydrogen obtained by one of processes (a)-(f) above.

It will also be appreciated that those compounds of formula I in which R<sup>3</sup> contains an acyloxy group, for example where R<sup>3</sup> is (1-4C)alkanoyloxyphenyl or (1-4C)alkanoyloxyphenyl(1-6C)alkyl, may be prepared by acylating the corresponding compounds of formula I in which R<sup>3</sup> comprises a hydroxy group, as for example 10 where R<sup>3</sup> is hydroxyphenyl or hydroxyphenyl(1-4C)alkyl. The acylation may be conducted by reaction with any conventional acylating agent, for example a (1-4C)alkanoyl halide or (1-4C)alkanoic acid anhydride.

Whereafter, when a pharmaceutically acceptable salt is required, it may be obtained, for example, by reacting a compound of formula I with the appropriate acid or base affording a physiologically acceptable ion or 15 another conventional procedure.

Similarly, when an optically active form of a chiral compound of formula I is required, either one of processes (a)-(f) above may be carried out using the appropriate optically active starting material or else a racemic form may be resolved by a conventional procedure, for example, using an optically active form of a suitable acid.

20 The starting materials used in the processes according to the invention are either known or may be prepared using techniques well known in the arts of heterocyclic and organic chemistry.

Thus the compounds of formula II in which Z<sup>1</sup> represents a halogen atom may be prepared from a compound of formula IX in which R<sup>12</sup> represents a hydrogen atom or an alkoxy group (for example ethyl) and R<sup>13</sup> and R<sup>14</sup> are as defined for R<sup>10</sup> and R<sup>11</sup> above according to the method of process (c) above, but using as the 25 dehydrating agent a reagent which is also a halogenating agent, for example phosphorus oxychloride. The reaction may be performed in the presence or absence of a solvent (such as dimethylformamide) at a temperature in the range of from 0 to 150 °C.

The compounds of formula III may be prepared by reacting a compound of formula X with a reducing agent, for example sodium dithionite, conveniently in the presence of a solvent such as aqueous ethanol. Compounds 30 of formula III in which R<sup>2</sup> represents a group capable of functioning as a leaving group, for example a (1-4C)alkylthio group (such as methylthio) may also be converted into other compounds of formula III by reaction with a nucleophilic compound of formula R<sup>3</sup>XH where X is, for example, NH. The reaction may conveniently be performed in the presence of a solvent such as water at a temperature in the range of from 40 to 120 °C.

The compounds of formula V in which one of R<sup>10</sup> and R<sup>11</sup> is a group of formula C(=X<sup>4</sup>)Q may be prepared 35 by reacting a compound of formula III with a compound of formula IV in which R<sup>9</sup> is a leaving group such as a halogen atom (for example a chlorine atom). The reaction is conveniently performed in the presence of a solvent such as chloroform and in the presence of a base such as triethylamine. The temperature at which the reaction is performed is conveniently in the range of from 0 to 100 °C. Compounds of formula V in which R<sup>2</sup> represents a group capable of functioning as a leaving group, for example a (1-4C)alkylthio group (such as 40 methylthio) may also be converted into other compounds of formula V by reaction with a nucleophilic compound of formula R<sup>3</sup>XH where X is, for example, NH. The reaction may conveniently be performed in the presence of a solvent such as water at a temperature in the range of from 40 to 120 °C.

The compounds of formula VI may be prepared by conventional methods. For example, the compounds of formula VI in which A is -N=CQ-CH=N- may be prepared according to the method described in J. Het. Chem., 45 25, 1737-1740, 1988.

The compounds of formula VIII may be prepared by methods analogous to those which may be used to prepare compounds of formula I. Compounds of formula VIII in which Z<sup>2</sup> represents a (1-4C)alkylsulphonyl group may be prepared by reacting a compound of formula I in which R<sup>2</sup> represents a (1-4C)alkylthio group 50 with an oxidising agent such as peracetic, perbenzoic or chloroperbenzoic acid. The oxidation may conveniently be performed in the presence of a solvent such as dichloromethane at a temperature in the range of from 0 to 40 °C.

The compounds of formula IX may be prepared by reacting a compound of formula VII with a compound of formula (R<sup>15</sup>OOC)CHNHCOQ in which R<sup>15</sup> is a (1-4C)alkyl group such as ethyl, or with a compound of formula XII (preparable by reacting a compound of formula (R<sup>15</sup>OOC)CHNHCOQ with a dehydrating agent such 55 as phosphorus pentoxide supported on silicon dioxide). The reaction is conveniently performed in the presence of a base, such as sodium methoxide or potassium carbonate, and a solvent such as dimethylformamide. The temperature at which the reaction is performed is conveniently in the range of from 25 to 120 °C.

The compounds of formula X may be prepared by reacting a compound of formula XI with an alkali metal

nitrite in the presence of an acid such as hydrochloric acid. The reaction is conveniently performed in the presence of a solvent such as aqueous ethanol at a temperature in the range of from 25 to 100 °C. The compounds of formula X may also be prepared by reacting a compound of formula VII with an appropriate oxime. For example, a compound in which X is O may be prepared using  $\text{NCC}(\text{COOEt})=\text{NOH}$  as the oxime.

5 Certain of the starting materials used in the processes according to the invention are believed to be novel, for example the compounds of formulae II and VIII, and these are provided as further aspects of the invention.

As stated above, the compounds of formula I possess the property of antagonising one or more of the physiological actions of adenosine and are valuable in the treatment of diseases and medical conditions affecting the mammalian cardiac, peripheral and/or cerebral vascular systems, such as ischaemic heart disease, 10 peripheral vascular disease (claudication) and cerebral ischaemia. The compounds may also be useful in the treatment of migraine.

The effects of compounds of formula I as adenosine receptor antagonists may be demonstrated in one or more of the following standard *in vitro* and/or *in vivo* tests.

#### 15 (a) $A_2$ Adenosine receptor affinity test

This test involves the ability of a test adenosine antagonist to displace the known adenosine mimetic agent  $[\text{3H}]\text{-N-ethylcarboxamidoadenosine}$  (NECA) from binding sites on membrane preparations derived from the rat 10 phaeochromocytoma cell line PC 12 (available from the Beatson Institute, Glasgow). The basic procedure has been described by Williams *et al.* (*J. Neurochemistry*, 1987, 48(2), 498-502).

The membrane preparation is obtained as follows:

Frozen pellets of PC12 cells are washed twice with ice cold, buffered, physiological saline and the cells recovered by centrifugation (1500G) at 3°C. The separated cells are then suspended in hypotonic solution (distilled water), allowed to stand on ice for 30 minutes and are then carefully homogenized using a standard high-speed homogeniser with periodic ice-cooling to obtain a fine suspension. The homogenate is centrifuged 25 (48000G) and the pellet is resuspended in 50 mM tris-HCl buffer, pH 7.4 containing adenosine deaminase (5 units/ml, Type VII from calf intestinal mucosa, available from Sigma Chemical Corporation, under reference no. A1280). The mixture is then incubated at 37°C. After 20 minutes, the reaction is terminated by dilution with ice-cold buffer and transfer onto ice. The material obtained containing the cell membranes is recovered by centrifugation and washed by resuspension in buffer and recentrifugation. The pellet produced is then resuspended 30 in ice-cold buffer using a hand-driven homogenizer. The resultant membrane suspension is frozen and stored under liquid nitrogen until required.

Binding studies are carried out in microtitre plates, the assay mixtures being buffered in 50 mM tris-HCl, pH 7.4 at room temperature. The test compound is dissolved in dimethyl sulphoxide (DMSO) and then diluted 35 with assay buffer to give the test solutions. [The final concentration of DMSO is not allowed to exceed 1% by volume, at which level it does not affect radioligand binding to the membrane receptor.] Incubations are performed at 30°C for 90 minutes in a total volume of 150  $\mu\text{l}$  comprising the test solution or buffer (50  $\mu\text{l}$ ), tritiated NECA (50  $\mu\text{l}$ ) and membrane suspension (50  $\mu\text{l}$ ). After incubation, the samples are rapidly filtered over glass-fibre mats and the filter mats are washed to remove non-receptor-bound radioligand. Receptor-bound radioligand 40 entrapped on the filter mats is then determined by liquid scintillation counting. Filtration and washing are carried out using a conventional vacuum filtration cell harvester. The specific binding (defined as the difference between the total binding and the non-specific binding) in the presence of the particular test compound is determined and compared with the control value. Results are conveniently expressed as the negative logarithm of the concentration required to cause a 50% displacement of control specific binding ( $\text{pIC}_{50}$ ).

45 In general, compounds of the formula I showing antagonist activity in this assay typically show a  $\text{pIC}_{50}$  in the above test (a) of 6 or more. Thus for example, the compound of Example 1 herein showed a 78% displacement of control binding at a concentration of  $10^{-6}\text{M}$  and 59% displacement at  $10^{-7}\text{M}$ , indicating a  $\text{pIC}_{50}$  of greater than 7. Using the same test procedure, the known compound 1,3-dimethylxanthine typically shows a  $\text{pIC}_{50}$  of about 5.

50

#### (b) Guinea-pig Atrial Bradycardic Test

This test has also been described by Collis *et al.* (*British J. Pharmacology*, 1989, 97, 1274-1278) and involves the ability of a test compound to antagonise the bradycardic effect of the adenosine mimetic, 2-chloro- 55 oadenosine, in a beating guinea-pig atrial preparation, an effect mediated via the adenosine receptor known as  $A_1$ .

The atrial pair preparation may be obtained as follows:-

Atrial pairs are obtained from guinea-pigs (Dunkin Hartley strain, 250-400g males) and mounted in organ baths

containing oxygenated Krebs buffer solution (95% O<sub>2</sub>; 5% CO<sub>2</sub>) at 37°C. The spontaneously beating atria are then placed under a resting tension of 1 g and allowed to equilibrate for 50 minutes with continuous overflow. Overflow is then stopped and adenosine deaminase (1 Unit/ml) added to prevent the accumulation of endogenously produced adenosine. After equilibration for 15 minutes, a cumulative dose response curve to the adenosine mimetic, 2-chloroadenosine (10<sup>-8</sup>M to 10<sup>-4</sup>M) is administered to produce a maximal slowing of atrial rate. After washout during 30 minutes, adenosine deaminase is readministered to the bath which is allowed to equilibrate for 15 minutes. A 10<sup>-5</sup>M solution of the test compound in DMSO is then added to the bath which is left to incubate for 30 minutes. Any effect on the beating rate due to the test compound is noted before the dose response curve to 2-chloroadenosine is repeated. Compounds which are adenosine antagonists attenuate the

Test compounds are assessed by comparing dose response curves to 2-chloroadenosine alone with those obtained in the presence of the compound. Competitive adenosine antagonists produce a parallel shift in the 2-chloroadenosine dose response curve. The dose ratio (DR) is calculated from the ratio of the concentration of 2-chloroadenosine to produce a 50% reduction in atrial rate (ED<sub>50</sub>) in the presence of the test compound divided by the ED<sub>50</sub> concentration of 2-chloroadenosine in the absence of the test compound for each atrial pair. The pA<sub>2</sub>, which is an estimate of the concentration of antagonist required to give a dose ratio of 2, may be calculated using a standard computational technique. In this test, the known compound, 1,3-dimethylxanthine, typically shows a pA<sub>2</sub> of about 5.

#### 20 (c) Anaesthetised cat blood pressure Test

This test assesses the ability of a test compound to antagonise the fall in diastolic blood pressure produced by administration of the adenosine mimetic, 2-chloroadenosine.

Male cats (2 - 3 kg) are anaesthetised with sodium pentobarbitone (45 mg/kg, ip). The following blood vessels are catheterised: right jugular vein (for infusion of the anaesthetic at approximately 7 mg/kg per hour as a 3 mg/ml solution in isotonic saline), the left jugular vein (for administration of test agents) and the right common carotid artery (for monitoring blood pressure and pulse rate). The blood gas status and pH are determined, and are maintained within physiological limits, before administration of 2-chloroadenosine. A control dose response curve (DRC) to 2-chloroadenosine (0.3 to 30 µg/kg) against the fall in diastolic blood pressure is determined. A solution of the test compound in a mixture of 50% v/v polyethylene glycol (PEG) 400 and 0.1M sodium hydroxide is then administered i.v. and after 15 minutes the DRC to 2-chloroadenosine is determined. This procedure is repeated twice with blood gases and pH being monitored and maintained within physiological limits between each DRC. The concentration of 2-chloroadenosine required to cause a 30 mm Hg fall in diastolic blood pressure is then calculated for each dose of test compound and a Schild plot constructed for those which produce a dose ratio (DR) of >2. From this plot a K<sub>B</sub> value is determined. Test compounds which are active in this test will possess a K<sub>B</sub> value of 1 mg/kg (or much less).

The above Test (c) may conveniently be modified to allow evaluation of orally administered test compounds by administering the test compound to conscious cats with indwelling arterial and venous catheters and measuring the effect in preventing an adenosine induced decrease in blood pressure. Test compounds which are orally active in this test will show significant adenosine antagonist activity at a dose of 1 - 3 mg/kg or less.

#### (d) Anaesthetised dog Test

This test involves the assessment of the effects of a test compound on antagonising the actions of adenosine in lowering heart rate and producing vasodilation (as measured by a fall in hind-limb perfusion pressure).

Beagles (12 - 18 kg) are anaesthetised with sodium pentobarbitone (50 mg/kg, iv). The following blood vessels are catheterised: right jugular vein (for infusion of the anaesthetic at approximately 112 mg per hour as a 3 mg/ml solution in isotonic saline), right brachial vein (for administration of drugs and test agents), right brachial artery (for measurement of systemic blood pressure and pulse rate) and the left carotid artery (for administration of adenosine into the left ventricle). Both vagi, the right femoral and sciatic nerves are ligated and severed. A bolus injection of 1250 U heparin is administered before perfusing the right hindlimb at constant blood flow with blood from the iliac artery. The right leg is tied just below the ankle. Xamoterol (1 mg/kg) is then administered to the animal to stabilise heart rate at a high level and nitrobenzylthioinosine (NBTI, 0.5 mg/kg) to inhibit the uptake of adenosine. The animal is sensitised to adenosine during the equilibration time following NBTI by carrying out a dose response curve (DRC). During this time any blood gas or pH imbalance is corrected. A control DRC is performed followed by up to three DRC's after cumulative administration of the test compound (as described in (d) above). Each DRC is carried out 15 minutes after administration of test compound and after the measured parameters of heart rate and hindlimb perfusion pressure have returned



to a stable state. Similarly, blood gases and pH are maintained within physiological limits throughout the evaluation.

The amount of adenosine required to cause a 50% fall in measured parameter ( $ED_{50}$ ) i.e. heart rate and hindlimb perfusion pressure is calculated for each dose of test compound and a Schild plot constructed. From this plot a  $K_B$  value is determined for antagonism of heart rate response and vasodilator response to adenosine. Test compounds which are active in this test will possess a  $K_B$  value of 1 mg/kg (or much less) for vasodilator response to adenosine.

#### (e) Anaesthetised cat exercise hyperaemia test

This test involves assessment of the effect of a test compound to antagonise the vasodilatation response which occurs during twitch contraction of skeletal muscle. The vasodilation is mediated partly by the release of endogenous adenosine from the contracting skeletal muscle.

Cats (2.4-3.6 kg) are anaesthetised with sodium pentobarbitone (50 mg.kg<sup>-1</sup> ip). The following blood vessels are catheterized: left jugular vein (for infusion of anaesthetic, at approximately 0.12 mg<sup>-1</sup>min<sup>-1</sup> as a 6 mg.ml<sup>-1</sup> solution in isotonic saline), right external jugular vein (for administration of drugs and test compounds), right common carotid artery (for measurement of systemic arterial blood pressure and pulse rate) and right brachial artery (for withdrawal of blood).

Blood flow to the left hind limb is measured with an electromagnetic flow probe around the left external iliac artery. The whole of the left hind limb is made to contract at 3Hz for 20 minutes duration by stimulating the sciatic and femoral nerves. Active tension produced by the extensor digitorum longus and peroneus longus muscles is measured isometrically with a force transducer. Exercise is repeated twice within the same animal, in either the absence or presence of the test compound. Test compounds are assessed for their ability to reduce the vasodilatation during skeletal muscle contraction. Test compounds which are active in this test will show significant inhibition of vasodilation during exercise at a dose of 1 mg/kg (or much less).

The compounds of the invention are generally best administered to warm-blooded animals for therapeutic or prophylactic purposes in the treatment or prevention of cardiovascular diseases and adverse conditions in the form of a pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt thereof, in a mixture or together with a pharmaceutically acceptable diluent or carrier. Such compositions are provided as a further feature of the invention.

In general, it is envisaged that a compound of formula I will be administered orally, intravenously or by some other medically acceptable route (such as by inhalation, insufflation, sub-lingual or transdermal means) so that a dose in the general range, for example, 0.001 mg to 10 (and more particularly in the range, for example, 0.05 to 5 mg/kg) mg/kg body weight is received. However, it will be understood that the precise dose administered will necessarily vary according to the nature and severity of the disease or condition being treated and on the age and sex of the patient.

A composition according to the invention may be in a variety of dosage forms. For example, it may be in the form of tablets, capsules, solutions or suspensions for oral administration; in the form of a suppository for rectal administration; in the form of a sterile solution or suspension for administration by intravenous or intramuscular injection; in the form of an aerosol or a nebuliser solution or suspension, for administration by inhalation; in the form of a powder, together with pharmaceutically acceptable inert solid diluents such as lactose, for administration by insufflation; or in the form of a skin patch for transdermal administration. The compositions may conveniently be in unit dose form containing, for example, 5 - 200 mg of the compound of formula I or an equivalent amount of a pharmaceutically acceptable salt thereof.

The compositions may be obtained by conventional procedures using pharmaceutically acceptable diluents and carriers well known in the art. Tablets and capsules for oral administration may conveniently be formed with an enteric coating (such as one based on cellulose acetate phthalate) to minimise the contact of the active ingredient of formula I with stomach acids.

The compositions of the invention may also contain one or more agents known to be of value in the diseases or conditions of the cardiovascular system intended to be treated. Thus, they may contain, in addition to the compound of formula I, for example: a known platelet aggregation inhibitor, prostanoid constrictor antagonist or synthase inhibitor (thromboxane A<sub>2</sub> antagonist or synthase inhibitor), cyclooxygenase inhibitor, hypolipidemic agent, anti-hypertensive agent, inotropic agent, beta-adrenergic blocker, thrombolytic agent or a vasodilator.

In addition to their use in therapeutic medicine, the compounds of formula I are also useful as pharmacological tools in the development and standardisation of test systems for the evaluation of new cardiovascular agents in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice.

The invention will now be illustrated by the following non-limiting Examples in which, unless otherwise stated:-

- (i) evaporations were carried out by rotary evaporation in vacuo;  
 (ii) operations were carried out at room temperature, that is in the range 18-26°C;  
 (iii) flash column chromatography or medium pressure liquid chromatography (MPLC) was performed on silica gel [either Fluka Kieselgel 60 (catalogue no. 60738) obtained from Fluka AG, Buchs, Switzerland,  
 5 or Merck Kieselgel Art. 9385, obtained from E Merck, Darmstadt, Germany];  
 (iv) yields are given for illustration only and are not necessarily the maximum attainable by diligent process development;  
 (v) proton NMR spectra were normally determined at 200 MHz in deuterated dimethyl sulphoxide as solvent, using tetramethylsilane (TMS) as an internal standard, and are expressed as chemical shifts (delta values) in parts per million relative to TMS using conventional abbreviations for designation of major peaks:  
 10 s, singlet; m, multiplet; t, triplet; br, broad; d, doublet; q, quartet; and  
 (vi) all end-products were characterised by microanalysis, NMR and/or mass spectroscopy.

**EXAMPLE 1**

7-chloro-2-(2-furyl)-5-[2-(4-methoxyphenyl)ethyl]amino-oxazolo[5,4-d]pyrimidine (0.5g) and ammonium chloride (0.1g) were added to a saturated solution of ammonia in ethanol (20ml) and sealed in a Caries tube. The sealed tube was then heated at 100°C for 18 hours. The cooled reaction mixture was poured into water (200ml) and the resultant precipitate removed by filtration. The solid was recrystallised from methanol to afford  
 20 **7-amino-2-(2-furyl)-5-[2-(4-methoxyphenyl)ethyl]amino-oxazolo[5,4-d]pyrimidine** (0.23g, 48.6%), m.p. 194-196°C; microanalysis, found: C, 61.5; H, 4.8; N, 19.5%;  $C_{18}H_{17}N_5O_3$  requires: C, 61.5; H, 4.9; N, 19.9%; NMR (DMSO-d<sub>6</sub>): 2.76 (t, 2H, ArCH<sub>2</sub>), 3.44 (brq 2H, CH<sub>2</sub>NH), 3.72 (s, 3H, OMe), 6.70 (m, 1H, furyl-H), 6.28 (brs, 1H, NH), 6.84 (d, 2H, ArH), 7.13 (complex, 5H, ArH, NH<sub>2</sub>, furyl-H), 7.89 (m, 1H, furyl-H); m/e [M+H]<sup>+</sup> 352.

The required starting material was prepared as follows:-

25 1) [(2-furanylcarbonyl)amino]propanedioic acid, diethyl ester (123g, 457mM) was added to a stirred mixture of 2-methyl-2-thio-pseudourea sulphate (63.8g, 229mM) and sodium methoxide (25% w/w) (105ml), in methanol (500ml).

The mixture was stirred at ambient temperature for 15hrs, then heated under reflux for 24 hours. Further sodium methoxide solution (260ml) was added and the mixture refluxed for a further 24 hours, cooled, poured into water and acidified with concentrated hydrochloric acid to PH<3. The mixture was then cooled to 0°C for 4 hours and the resultant precipitate separated by filtration. The solid was washed with methylene chloride, then acetone, and air-dried. Further purification was achieved by suspension in hot water for 0.5 hours. The solid was filtered off and dried at 70°C for 15 hours in a vacuum oven. This gave 4,6-dihydroxy-5-(2-furanylcarbonyl)amino-2-methylthiopyrimidine (22.5g) as a white solid (yield 18.5%) m.p. 124-125°C. NMR: NaOD; 2.66 (s, 3H, SMe), 4.04 (s, 1H, NH), 6.83 (m, 1H, furyl-H), 7.39 (d, 1H, furyl-H), 7.88 (m, 1H, furyl-H); m/e [M+NH<sub>4</sub>]<sup>+</sup> 285:

2) A mixture of 4,6-dihydroxy-5-(2-furanylcarbonyl)amino-2-methylthiopyrimidine (2g, 7.5mM), p-methoxyphenethylamine (3.4g, 22.5mM), and water (25ml) was heated at 90°C for 15 hours. The mixture was then poured into water (100ml) and acidified with concentrated hydrochloric acid until PH<3. The resultant precipitate was removed by filtration and recrystallised from methanol/water (3:1) to afford 4,6-dihydroxy-5-(2-furanylcarbonyl)amino-2-[(4-methoxyphenyl)ethyl]aminopyrimidine as a white solid (0.46g, 16.6% yield) m.p. >250°C; NMR: DMSO-d<sub>6</sub>: 2.75 (t, 2H, ArCH<sub>2</sub>), 3.47 (brq, 2H, CH<sub>2</sub>NH), 3.73 (s, 3H, OMe), 6.50 (brs, 1H, NH), 6.61 (m, 1H, furyl-H), 6.87 (d, 2H, ArH), 7.16 (d, 2H, ArH), 7.17 (s, 1H, furyl-H), 7.82 (d, 1H, furyl-H), 8.64 (brs, 1H, NHCO), 10.58 (brs, 2H, OH x 2); m/e [M+H]<sup>+</sup>, 371:

3) A mixture of 4,6-dihydroxy-5-(2-furanylcarbonyl)amino-2-[(4-methoxyphenyl)ethyl]aminopyrimidine (408mg) and phosphorus oxychloride (5ml) was heated at 90°C for 3 hours. The excess phosphorus oxychloride was removed by evaporation, in vacuo, and then by azeotroping with toluene (2 x 50ml). The residue was added to water and the resultant precipitate filtered off, washed with water and dried. There was thus produced 7-chloro-2-(2-furyl)-5-[2-(4-methoxyphenyl)ethyl]amino oxazolo[5,4-d]pyrimidine (340mg, 83.2% yield); m.p. 169.5 - 171°C; NMR: DMSO-d<sub>6</sub>: 2.80 (t, 2H, ArCH<sub>2</sub>), 3.48 (q, 2H, CH<sub>2</sub>NH), 3.72 (s, 3H, OMe), 6.80 (m, 1H, furyl-H), 6.85 (d, 2H, ArH), 7.16 (d, 2H, ArH), 7.44 (d, 1H, furyl-H), 8.07 (m, 1H, furyl-H), 8.13 (brs, 1H, NH).

**EXAMPLE 2**

7-Amino-5-[2-(3,4-dimethoxyphenyl)ethyl]amino-2-(2-furyl)-oxazolo[5,4-d]pyrimidine was prepared using a procedure similar to that described in Example 1, as a white solid (recrystallised from methanol/hexane); m.p. 155-158°C; microanalysis, found: C. 59.4; N, 5.0; N, 18.4%;  $C_{19}H_{19}N_5O_4$  requires: C, 59.8;

H, 5.0; N, 18.4%; NMR (DMSO-d<sub>6</sub>): 2.77(t, 2H, ArCH<sub>2</sub>), 3.45(q, 2H, CH<sub>2</sub>NH), 3.72(s, 3H, OMe), 3.75 (s, 3H, OMe), 6.70(complex, 5H, NH, 3 x ArH, furyl-H), 7.14(d, 1H, furyl-H), 7.18 (brs, 2H, NH<sub>2</sub>), 7.92(m, 1H, furyl-H); m/e, [M+H]<sup>+</sup>, 382:

The required starting materials were prepared as in Example 1. This gave 4,6-dihydroxy-2-[(3,4-dimethoxyphenyl)ethyl]amino-5-(2-furanylcarbonyl)pyrimidine (45.6% yield) m.p. >250°C: NMR: DMSO-d<sub>6</sub>: 2.76(t, 2H, ArCH<sub>2</sub>), 3.49(q, 2H, NHCH<sub>2</sub>), 3.72(s, 3H, OMe), 3.75(s, 3H, OMe), 6.47(brs, 1H, NHCH<sub>2</sub>), 6.61(m, 1H, furyl-H), 6.76(d, 1H, Ar-H), 6.86(m, 2H, Ar-H) 7.17(d, 1H, furyl-H), 7.82(brs, 1H, furyl-H), 8.64(s, 1H, NHCO), 10.62(brs, 2H, 2 x OH); m/e, [M+H]<sup>+</sup>, 401:

7-chloro-5-[(3,4-dimethoxyphenyl)ethyl]amino-2-(2-furyl)-oxazolo[5,4-d]pyrimidine (78% yield) m.p. 176-177°C: NMR; DMSO-d<sub>6</sub>): 2.80(t, 2H, ArCH<sub>2</sub>), 3.51(q, 2H, CH<sub>2</sub>NH), 3.71(s, 3H, OMe), 3.74(s, 3H, OMe), 6.78(complex, 4H, 3 x ArH, furyl-H), 7.43 (d, 1H, furyl-H), 8.06(m, 1H, furyl-H), 8.13(brs, 1H, NH). m/e [M+H]<sup>+</sup> 401.

### EXAMPLE 3

7-amino-5-(4-chlorobenzyl)-2-(2-furyl)-oxazolo[5,4-d]pyrimidine was prepared in a manner similar to that described in Example 1 except that no sealed tube was required and the reaction was carried out at ambient temperature using ammonia in isopropanol for 15 hours. The product was purified using flash column chromatography, eluting with methanol/chloroform (5/95). There was thus obtained a white solid m.p. >200°C; microanalysis, found; C, 58.8; H, 3.7%; C<sub>16</sub>H<sub>11</sub>N<sub>4</sub>O<sub>2</sub>Cl requires: C, 58.8; H, 3.4%; NMR; DMSO-d<sub>6</sub>: 4.00(s, 2H, ArCH<sub>2</sub>), 6.79(m, 1H, furyl-H), 7.3% (d, 1H, furyl-H), 7.33(s, 4H, ArH), 7.75(brs, 2H, NH<sub>2</sub>), 8.03 (d, 1H, furyl-H).

The starting material was prepared as follows:-

1) A mixture of [(2-furanylcarbonyl)amino]propanedioic acid, diethyl ester (53g, 0.2M) and acetonitrile (1 litre) was stirred at ambient temperature. Phosphorus pentoxide supported on silicon dioxide (90g) was then added slowly with brisk stirring. The mixture was heated to reflux for 2 hours and then allowed to cool over 15 hours. A further portion of phosphorus pentoxide supported on silicon dioxide (85g) was added, the mixture refluxed for seven hours and then cooled over 15 hours. The mixture was filtered through diatomaceous earth and the filtrate evaporated under reduced pressure to give a yellow gum. More of this product was obtained by extraction of the filter solids with ethyl acetate, followed by evaporation of the solvent under reduced pressure.

The gum was purified by flash column chromatography, eluting with ethyl acetate/hexane (1:4). The resultant solid was recrystallised from methanol/water to give 4-carboxyethyl-5-ethoxy-2-(2-furyl)-oxazole as a solid (12.5g, 25% yield); NMR: 1.28(t, 3H, CH<sub>3</sub>CH<sub>2</sub>O), 1.40(t, 3H, CH<sub>3</sub>CH<sub>2</sub>OOC), 4.25(q, 2H, CH<sub>3</sub>CH<sub>2</sub>O), 4.57(q, 2H, CH<sub>3</sub>CH<sub>2</sub>OOC), 6.71(m, 1H, furyl-H), 7.12(d, 1H, furyl-H), 7.92(d, 1H, furyl-H).

2) A mixture of 5-carboxyethyl-4-ethoxy-2-(2-furyl)-oxazole (4.0g, 0.016M), p-chlorobenzylamine hydrochloride (3.7g, 0.016M), anhydrous potassium carbonate (4.4g, 0.032M) and dry dimethylformamide (80ml) was heated at 100°C under argon for 3 hours. The solvent was then distilled off under reduced pressure and the residue partitioned between ethyl acetate and water. The ethyl acetate layer was separated, dried, and concentrated to give an oil. This was purified by flash column chromatography eluting with methanol/chloroform (1:9). There was thus obtained 2-p-chlorobenzyl-4-ethoxy-5-(2-furanylcarbonyl)amino-6-hydroxypyrimidine as a pink/white solid (2.2g, 35% yield) m.p. 91.5-92.5°C; NMR; 1.20(t, 3H, CH<sub>3</sub>CH<sub>2</sub>O), 3.91(s, 2H, ArCH<sub>2</sub>), 4.28 (q, 2H, CH<sub>3</sub>CH<sub>2</sub>O), 6.65(m, 1H, furyl-H), 7.71(d, 1H, furyl-H), 7.42(s, 4H, ArH), 7.86(m, 1H, furyl-H), 9.02 (s, 1H, NHCO), 12.70(brs, 1H, OH).

3. A mixture of 2-p-chlorobenzyl-4-ethoxy-5-(2-furanylcarbonyl)amino-6-hydroxypyrimidine (2.2g, 5.9mM), dimethylaniline (1.12ml, 9mM) and phosphorus oxychloride (20ml) was heated at reflux for 2 hours. The excess phosphorous oxychloride was distilled off under reduced pressure and the residue azeotroped (x 2) with toluene. The residue was partitioned between ethyl acetate and water. The ethyl acetate extracts were dried and the solvent removed under reduced pressure. The resultant solid was further purified by flash column chromatography, eluting with hexane/ethyl acetate (65:35). There was thus obtained 7-chloro-5-(4-chlorobenzyl)-2-(2-furyl)-oxazolo[5,4-d]pyrimidine (1.2g), which was used directly without being characterised.

### EXAMPLE 4

A mixture of 6-amino-8-(2-furyl)-2-[2-(4-methoxyphenyl)ethyl]amino-1H-purine (0.8g, 2.29mM), anhydrous potassium carbonate (0.347g, 2.52mM), iodomethane (157μl, 2.52mM) and dimethyl formamide (20ml) was stirred at ambient temperature under an argon atmosphere for 15 hours. The solvent was removed by distillation under reduced pressure and the residue purified by flash column chromatography eluting with me-

5  
 10  
 15  
 20  
 25  
 30  
 35  
 40  
 45  
 50  
 55  
 60  
 65  
 70  
 75  
 80  
 85  
 90  
 95  
 100  
 105  
 110  
 115  
 120  
 125  
 130  
 135  
 140  
 145  
 150  
 155  
 160  
 165  
 170  
 175  
 180  
 185  
 190  
 195  
 200  
 205  
 210  
 215  
 220  
 225  
 230  
 235  
 240  
 245  
 250  
 255  
 260  
 265  
 270  
 275  
 280  
 285  
 290  
 295  
 300  
 305  
 310  
 315  
 320  
 325  
 330  
 335  
 340  
 345  
 350  
 355  
 360  
 365  
 370  
 375  
 380  
 385  
 390  
 395  
 400  
 405  
 410  
 415  
 420  
 425  
 430  
 435  
 440  
 445  
 450  
 455  
 460  
 465  
 470  
 475  
 480  
 485  
 490  
 495  
 500  
 505  
 510  
 515  
 520  
 525  
 530  
 535  
 540  
 545  
 550  
 555  
 560  
 565  
 570  
 575  
 580  
 585  
 590  
 595  
 600  
 605  
 610  
 615  
 620  
 625  
 630  
 635  
 640  
 645  
 650  
 655  
 660  
 665  
 670  
 675  
 680  
 685  
 690  
 695  
 700  
 705  
 710  
 715  
 720  
 725  
 730  
 735  
 740  
 745  
 750  
 755  
 760  
 765  
 770  
 775  
 780  
 785  
 790  
 795  
 800  
 805  
 810  
 815  
 820  
 825  
 830  
 835  
 840  
 845  
 850  
 855  
 860  
 865  
 870  
 875  
 880  
 885  
 890  
 895  
 900  
 905  
 910  
 915  
 920  
 925  
 930  
 935  
 940  
 945  
 950  
 955  
 960  
 965  
 970  
 975  
 980  
 985  
 990  
 995  
 1000  
 1005  
 1010  
 1015  
 1020  
 1025  
 1030  
 1035  
 1040  
 1045  
 1050  
 1055  
 1060  
 1065  
 1070  
 1075  
 1080  
 1085  
 1090  
 1095  
 1100  
 1105  
 1110  
 1115  
 1120  
 1125  
 1130  
 1135  
 1140  
 1145  
 1150  
 1155  
 1160  
 1165  
 1170  
 1175  
 1180  
 1185  
 1190  
 1195  
 1200  
 1205  
 1210  
 1215  
 1220  
 1225  
 1230  
 1235  
 1240  
 1245  
 1250  
 1255  
 1260  
 1265  
 1270  
 1275  
 1280  
 1285  
 1290  
 1295  
 1300  
 1305  
 1310  
 1315  
 1320  
 1325  
 1330  
 1335  
 1340  
 1345  
 1350  
 1355  
 1360  
 1365  
 1370  
 1375  
 1380  
 1385  
 1390  
 1395  
 1400  
 1405  
 1410  
 1415  
 1420  
 1425  
 1430  
 1435  
 1440  
 1445  
 1450  
 1455  
 1460  
 1465  
 1470  
 1475  
 1480  
 1485  
 1490  
 1495  
 1500  
 1505  
 1510  
 1515  
 1520  
 1525  
 1530  
 1535  
 1540  
 1545  
 1550  
 1555  
 1560  
 1565  
 1570  
 1575  
 1580  
 1585  
 1590  
 1595  
 1600  
 1605  
 1610  
 1615  
 1620  
 1625  
 1630  
 1635  
 1640  
 1645  
 1650  
 1655  
 1660  
 1665  
 1670  
 1675  
 1680  
 1685  
 1690  
 1695  
 1700  
 1705  
 1710  
 1715  
 1720  
 1725  
 1730  
 1735  
 1740  
 1745  
 1750  
 1755  
 1760  
 1765  
 1770  
 1775  
 1780  
 1785  
 1790  
 1795  
 1800  
 1805  
 1810  
 1815  
 1820  
 1825  
 1830  
 1835  
 1840  
 1845  
 1850  
 1855  
 1860  
 1865  
 1870  
 1875  
 1880  
 1885  
 1890  
 1895  
 1900  
 1905  
 1910  
 1915  
 1920  
 1925  
 1930  
 1935  
 1940  
 1945  
 1950  
 1955  
 1960  
 1965  
 1970  
 1975  
 1980  
 1985  
 1990  
 1995  
 2000  
 2005  
 2010  
 2015  
 2020  
 2025  
 2030  
 2035  
 2040  
 2045  
 2050  
 2055  
 2060  
 2065  
 2070  
 2075  
 2080  
 2085  
 2090  
 2095  
 2100  
 2105  
 2110  
 2115  
 2120  
 2125  
 2130  
 2135  
 2140  
 2145  
 2150  
 2155  
 2160  
 2165  
 2170  
 2175  
 2180  
 2185  
 2190  
 2195  
 2200  
 2205  
 2210  
 2215  
 2220  
 2225  
 2230  
 2235  
 2240  
 2245  
 2250  
 2255  
 2260  
 2265  
 2270  
 2275  
 2280  
 2285  
 2290  
 2295  
 2300  
 2305  
 2310  
 2315  
 2320  
 2325  
 2330  
 2335  
 2340  
 2345  
 2350  
 2355  
 2360  
 2365  
 2370  
 2375  
 2380  
 2385  
 2390  
 2395  
 2400  
 2405  
 2410  
 2415  
 2420  
 2425  
 2430  
 2435  
 2440  
 2445  
 2450  
 2455  
 2460  
 2465  
 2470  
 2475  
 2480  
 2485  
 2490  
 2495  
 2500  
 2505  
 2510  
 2515  
 2520  
 2525  
 2530  
 2535  
 2540  
 2545  
 2550  
 2555  
 2560  
 2565  
 2570  
 2575  
 2580  
 2585  
 2590  
 2595  
 2600  
 2605  
 2610  
 2615  
 2620  
 2625  
 2630  
 2635  
 2640  
 2645  
 2650  
 2655  
 2660  
 2665  
 2670  
 2675  
 2680  
 2685  
 2690  
 2695  
 2700  
 2705  
 2710  
 2715  
 2720  
 2725  
 2730  
 2735  
 2740  
 2745  
 2750  
 2755  
 2760  
 2765  
 2770  
 2775  
 2780  
 2785  
 2790  
 2795  
 2800  
 2805  
 2810  
 2815  
 2820  
 2825  
 2830  
 2835  
 2840  
 2845  
 2850  
 2855  
 2860  
 2865  
 2870  
 2875  
 2880  
 2885  
 2890  
 2895  
 2900  
 2905  
 2910  
 2915  
 2920  
 2925  
 2930  
 2935  
 2940  
 2945  
 2950  
 2955  
 2960  
 2965  
 2970  
 2975  
 2980  
 2985  
 2990  
 2995  
 3000  
 3005  
 3010  
 3015  
 3020  
 3025  
 3030  
 3035  
 3040  
 3045  
 3050  
 3055  
 3060  
 3065  
 3070  
 3075  
 3080  
 3085  
 3090  
 3095  
 3100  
 3105  
 3110  
 3115  
 3120  
 3125  
 3130  
 3135  
 3140  
 3145  
 3150  
 3155  
 3160  
 3165  
 3170  
 3175  
 3180  
 3185  
 3190  
 3195  
 3200  
 3205  
 3210  
 3215  
 3220  
 3225  
 3230  
 3235  
 3240  
 3245  
 3250  
 3255  
 3260  
 3265  
 3270  
 3275  
 3280  
 3285  
 3290  
 3295  
 3300  
 3305  
 3310  
 3315  
 3320  
 3325  
 3330  
 3335  
 3340  
 3345  
 3350  
 3355  
 3360  
 3365  
 3370  
 3375  
 3380  
 3385  
 3390  
 3395  
 3400  
 3405  
 3410  
 3415  
 3420  
 3425  
 3430  
 3435  
 3440  
 3445  
 3450  
 3455  
 3460  
 3465  
 3470  
 3475  
 3480  
 3485  
 3490  
 3495  
 3500  
 3505  
 3510  
 3515  
 3520  
 3525  
 3530  
 3535  
 3540  
 3545  
 3550  
 3555  
 3560  
 3565  
 3570  
 3575  
 3580  
 3585  
 3590  
 3595  
 3600  
 3605  
 3610  
 3615  
 3620  
 3625  
 3630  
 3635  
 3640  
 3645  
 3650  
 3655  
 3660  
 3665  
 3670  
 3675  
 3680  
 3685  
 3690  
 3695  
 3700  
 3705  
 3710  
 3715  
 3720  
 3725  
 3730  
 3735  
 3740  
 3745  
 3750  
 3755  
 3760  
 3765  
 3770  
 3775  
 3780  
 3785  
 3790  
 3795  
 3800  
 3805  
 3810  
 3815  
 3820  
 3825  
 3830  
 3835  
 3840  
 3845  
 3850  
 3855  
 3860  
 3865  
 3870  
 3875  
 3880  
 3885  
 3890  
 3895  
 3900  
 3905  
 3910  
 3915  
 3920  
 3925  
 3930  
 3935  
 3940  
 3945  
 3950  
 3955  
 3960  
 3965  
 3970  
 3975  
 3980  
 3985  
 3990  
 3995  
 4000  
 4005  
 4010  
 4015  
 4020  
 4025  
 4030  
 4035  
 4040  
 4045  
 4050  
 4055  
 4060  
 4065  
 4070  
 4075  
 4080  
 4085  
 4090  
 4095  
 4100  
 4105  
 4110  
 4115  
 4120  
 4125  
 4130  
 4135  
 4140  
 4145  
 4150  
 4155  
 4160  
 4165  
 4170  
 4175  
 4180  
 4185  
 4190  
 4195  
 4200  
 4205  
 4210  
 4215  
 4220  
 4225  
 4230  
 4235  
 4240  
 4245  
 4250  
 4255  
 4260  
 4265  
 4270  
 4275  
 4280  
 4285  
 4290  
 4295  
 4300  
 4305  
 4310  
 4315  
 4320  
 4325  
 4330  
 4335  
 4340  
 4345  
 4350  
 4355  
 4360  
 4365  
 4370  
 4375  
 4380  
 4385  
 4390  
 4395  
 4400  
 4405  
 4410  
 4415  
 4420  
 4425  
 4430  
 4435  
 4440  
 4445  
 4450  
 4455  
 4460  
 4465  
 4470  
 4475  
 4480  
 4485  
 4490  
 4495  
 4500  
 4505  
 4510  
 4515  
 4520  
 4525  
 4530  
 4535  
 4540  
 4545  
 4550  
 4555  
 4560  
 4565  
 4570  
 4575  
 4580  
 4585  
 4590  
 4595  
 4600  
 4605  
 4610  
 4615  
 4620  
 4625  
 4630  
 4635  
 4640  
 4645  
 4650  
 4655  
 4660  
 4665  
 4670  
 4675  
 4680  
 4685  
 4690  
 4695  
 4700  
 4705  
 4710  
 4715  
 4720  
 4725  
 4730  
 4735  
 4740  
 4745  
 4750  
 4755  
 4760  
 4765  
 4770  
 4775  
 4780  
 4785  
 4790  
 4795  
 4800  
 4805  
 4810  
 4815  
 4820  
 4825  
 4830  
 4835  
 4840  
 4845  
 4850  
 4855  
 4860  
 4865  
 4870  
 4875  
 4880  
 4885  
 4890  
 4895  
 4900  
 4905  
 4910  
 4915  
 4920  
 4925  
 4930  
 4935  
 4940  
 4945  
 4950  
 4955  
 4960  
 4965  
 4970  
 4975  
 4980  
 4985  
 4990  
 4995  
 5000  
 5005  
 5010  
 5015  
 5020  
 5025  
 5030  
 5035  
 5040  
 5045  
 5050  
 5055  
 5060  
 5065  
 5070  
 5075  
 5080  
 5085  
 5090  
 5095  
 5100  
 5105  
 5110  
 5115  
 5120  
 5125  
 5130  
 5135  
 5140  
 5145  
 5150  
 5155  
 5160  
 5165  
 5170  
 5175  
 5180  
 5185  
 5190  
 5195  
 5200  
 5205  
 5210  
 5215  
 5220  
 5225  
 5230  
 5235  
 5240  
 5245  
 5250  
 5255  
 5260  
 5265  
 5270  
 5275  
 5280  
 5285  
 5290  
 5295  
 5300  
 5305  
 5310  
 5315  
 5320  
 5325  
 5330  
 5335  
 5340  
 5345  
 5350  
 5355  
 5360  
 5365  
 5370  
 5375  
 5380  
 5385  
 5390  
 5395  
 5400  
 5405  
 5410  
 5415  
 5420  
 5425  
 5430  
 5435  
 5440  
 5445  
 5450  
 5455  
 5460  
 5465  
 5470  
 5475  
 5480  
 5485  
 5490  
 5495  
 5500  
 5505  
 5510  
 5515  
 5520  
 5525  
 5530  
 5535  
 5540  
 5545  
 5550  
 5555  
 5560  
 5565  
 5570  
 5575  
 5580  
 5585  
 5590  
 5595  
 5600  
 5605  
 5610  
 5615  
 5620  
 5625  
 5630  
 5635  
 5640  
 5645  
 5650  
 5655  
 5660  
 5665  
 5670  
 5675  
 5680  
 5685  
 5690  
 5695  
 5700  
 5705  
 5710  
 5715  
 5720  
 5725  
 5730  
 5735  
 5740  
 5745  
 5750  
 5755  
 5760  
 5765  
 5770  
 5775  
 5780  
 5785  
 5790  
 5795  
 5800  
 5805  
 5810  
 5815  
 5820  
 5825  
 5830  
 5835  
 5840  
 5845  
 5850  
 5855  
 5860  
 5865  
 5870  
 5875  
 5880  
 5885  
 5890  
 5895  
 5900  
 5905  
 5910  
 5915  
 5920  
 5925  
 5930  
 5935  
 5940  
 5945  
 5950  
 5955  
 5960  
 5965  
 5970  
 5975  
 5980  
 5985  
 5990  
 5995  
 6000  
 6005  
 6010  
 6015  
 6020  
 6025  
 6030  
 6035  
 6040  
 6045  
 6050  
 6055  
 6060  
 6065  
 6070  
 6075  
 6080  
 6085  
 6090  
 6095  
 6100  
 6105  
 6110  
 6115  
 6120  
 6125  
 6130  
 6135  
 6140  
 6145  
 6150  
 6155  
 6160  
 6165  
 6170  
 6175  
 6180  
 6185  
 6190  
 6195  
 6200  
 6205  
 6210  
 6215  
 6220  
 6225  
 6230  
 6235  
 6240  
 6245  
 6250  
 6255  
 6260  
 6265  
 6270  
 6275  
 6280  
 6285  
 6290  
 6295  
 6300  
 6305  
 6310  
 6315  
 6320  
 6325  
 6330  
 6335  
 6340  
 6345  
 6350  
 6355  
 6360  
 6365  
 6370  
 6375  
 6380  
 6385  
 6390  
 6395  
 6400  
 6405  
 6410  
 6415  
 6420  
 6425  
 6430  
 6435  
 6440  
 6445  
 6450  
 6455  
 6460  
 6465  
 6470  
 6475  
 6480  
 6485  
 6490  
 6495  
 6500  
 6505  
 6510  
 6515  
 6520  
 6525  
 6530  
 6535  
 6540  
 6545  
 6550  
 6555  
 6560  
 6565  
 6570  
 6575  
 6580  
 6585  
 6590  
 6595  
 6600  
 6605  
 6610  
 6615  
 6620  
 6625  
 6630  
 6635  
 6640  
 6645  
 6650  
 6655  
 6660  
 6665  
 6670  
 6675  
 6680  
 6685  
 6690  
 6695  
 6700  
 6705  
 6710  
 6715  
 6720  
 6725  
 6730  
 6735  
 6740  
 6745  
 6750  
 6755  
 6760  
 6765  
 6770  
 6775  
 6780  
 6785  
 6790  
 6795  
 6800  
 6805  
 6810  
 6815  
 6820  
 6825  
 6830  
 6835  
 6840  
 6845  
 6850  
 6855  
 6860  
 6865  
 6870  
 6875  
 6880  
 6885  
 6890  
 6895  
 6900  
 6905  
 6910  
 6915  
 6920  
 6925  
 6930  
 6935  
 6940  
 6945  
 6950  
 6955  
 6960

**EXAMPLE 9**

**6-Amino-8-(2-furyl)-9-methyl-2-methylthio-1H-purine**; m.p. >250°C; microanalysis, found; C, 50.5; H, 4.1; N, 26.6%;  $C_{11}H_{11}N_5OS$  requires; C, 50.6; H, 4.24; N, 26.8%; NMR; DMSO- $d_6$ ; 2.5(s, 3H,  $SCH_3$ ), 3.8 - 3.9 (s, 3H,  $N-CH_3$ ), 6.75(m, 1H, furan-H), 7.15 (d, 1H, furan-H), 7.3-7.5 (b, 2H,  $NH_2$ ), 7.9-8.0 (d, 1H, furan-H).

**EXAMPLES 10 - 14**

The following compounds were prepared following the method described in Example 5, but using the appropriate triaminopyrimidine.

**EXAMPLE 10**

**6-Amino-2-[2-(3,4-dimethoxyphenyl)ethyl]amino-8-(2-furyl)-1H-purine**, m.p. 209°C (with decomposition); microanalysis, found; C, 55.9; H, 5.4; N, 20.2%;  $C_{19}H_{20}N_6O_3$  (1 1/2  $H_2O$ ) requires; C, 56.0; H, 5.7; N, 20.6%; NMR; DMSO- $d_6$ ; 2.7 - 2.9 (t, 2H,  $CH_2-CH_2$ ), 3.4-3.6(m, 2H,  $CH_2NH$ ), 3.7-3.8(d, 6H,  $OCH_3 \times 2$ ), 6.6-6.7 (b, 1H, furan-H), 6.7 - 6.9 (m, 3H, aromatic-H), 7.0 (b, 1H, furan-H), 7.8-7.85(b, 1H, furan-H) >10 ( $NH$  and  $NH_2$ ). m/e  $[M+H]^+$  381.

**EXAMPLE 11**

**6-Amino-8-(2-furyl)-2-[2-(4-methylphenyl)ethyl]amino-1H-purine**, m.p. 235-237°C (with decomposition); microanalysis, found; C, 59.2; H, 5.5; N, 21.4%;  $C_{18}H_{18}N_6O \cdot 0.5CH_3COOH \cdot H_2O$  requires; C, 59.6; H, 5.5; N, 21.9%; NMR; DMSO- $d_6$  1.85(s, 1 1/2H, 1/2 $CH_3COOH$ ), 2.25 (s, 3H,  $CH_3$ ), 2.7-2.9 (t, 2H,  $CH_2-CH_2$ ), 3.4-3.55(q, 2H,  $NHCH_2$ ), 6.1(t, 1H,  $NH$ ), 6.65 (m, 2H,  $NH_2$ ), 7.0 (d, 1H, furan-H), 7.05-7.2 (m, 4H, aromatic-H), 7.8 (m, 1H, furan-H).

**EXAMPLE 12**

**6-Amino-8-(2-furyl)-2-[2-phenylethyl]amino-1H-purine**, m.p. >240°C; microanalysis, found; C, 61.4; H, 4.9; N, 25.2%;  $C_{17}H_{16}N_6O$  (0.6  $H_2O$ ) requires; C, 61.7; H, 5.5; N, 25.3%; NMR; DMSO- $d_6$ ; 2.85 (m, 2H,  $CH_2Ph$ ), 3.50 (m, 2H,  $CH_2NH$ ), 6.1-6.25 (b, 1H,  $NH$ ), 6.55-6.75(b, 3H,  $NH_2$  + furan-H), 6.95(d, 1H, furan-H), 7.15-7.4(m, 5H, aromatic H), 7.8(s, 1H, furan-H), 12.6 (b, 1H,  $NH$ ).

**EXAMPLE 13**

**6-Amino-2-benzylthio-8-(2-furyl)-1H-purine**; m.p. 234°C (with decomposition); microanalysis, found; C, 59.5; H, 4.1; N, 21.3%;  $C_{16}H_{13}N_5OS$  requires; C, 59.4; H, 4.1; N, 21.7%; NMR; DMSO- $d_6$ ; 4.3-4.4 (s, 2H,  $CH_2-S$ ), 6.7(m, 1H, furan-H), 7.1(d, 1H, furan-H), 7.15-7.5 (m, 7H, aromatic-H+  $NH_2$ ), 7.9 (d, 1H, furan-H), 13.1-13.4 (brs, 1H,  $NH$ ).

**EXAMPLE 14**

**6-Amino-8-(2-furyl)-2-methylthio-1H-purine**; m.p. >250°C; NMR; DMSO- $d_6$ ; 2.4-2.5 (s, 3H,  $SCH_3$ ), 2.8-3.8 (br, 1H,  $NH$ ), 6.7(d, 1H, furan-H), 7.1 (d, 1H, furan-H), 7.1-7.25 (s, 2H,  $NH_2$ ), 7.8-7.9(d, 1H, furan-H).

The starting materials for Examples 10, 11, 12 were prepared as described in Example 5 starting from 4,6-diamino-2-methylthio-5-nitrosopyrimidine.

4,6-diamino-2-(2-phenylethyl)amino-5-nitrosopyrimidine; m/e  $[M+H]^+$  259;

4,6-diamino-2-[2-(3,4-dimethoxyphenyl)ethyl]amino-5-nitrosopyrimidine m/e  $[M+H]^+$  319;

4,6-diamino-2-[2-(4-methoxyphenyl)ethyl]amino-5-nitrosopyrimidine; 2-(2-phenylethyl)amino-4,5,6-triaminopyrimidine; m/e  $[M+H]^+$  245;

2-[2-(3,4-dimethoxyphenyl)ethyl]amino-4,5,6-triaminopyrimidine; m/e  $[M+H]^+$  305; and

2-[2-(4-methylphenyl)ethyl]amino-4,5,6-triaminopyrimidine; m/e  $[M+H]^+$  258.

**EXAMPLE 15**

A mixture of 4-amino-5-(2-furanylcarbonyl)amino-6-hydroxy-2-(2-phenyl)ethylpyrimidine (0.4g) and phosphorus oxychloride (5ml) was heated at reflux for 30 minutes. The excess phosphorus oxychloride was re-

moved by distillation under reduced pressure followed by azeotroping with toluene ( x 2 ). The mixture was separated between chloroform and water. The organic layer was separated, dried and the solvent distilled off under reduced pressure. The solid produced was purified by flash column chromatography eluting with methanol/methylene chloride (3:97). There was thus produced **7-amino-2-(2-furyl)-5-(2-phenyl)ethyloxazolo[5,4-d]pyrimidine** (0.18g, 50% yield); m.p. 206-208°C; microanalysis, found: C, 66.0; H, 4.6; N, 18.2%;  $C_{17}H_{14}N_4O_2 \cdot (0.25H_2O)$  requires: C, 65.7; H, 4.7; N, 18.0%; NMR; DMSO- $d_6$ : 2.9 - 3.15(m, 4H,  $CH_2 \times 2$ ), 6.8(m, 1H, furan-H), 7.1-7.3 (m, 5H, aromatic-H), 7.35 (m, 1H, furan-H), 7.65-7.75 (b, 2H,  $NH_2$ ), 6.0 (m, 1H, furan-H).

The starting material was prepared as follows:-

- a) A mixture of sodium (0.25g, 10.8mM) and ethanol (30ml) was stirred at ambient temperature under an argon atmosphere until all the metal had dissolved. 2-Phenylethylamine hydrochloride (1.0g, 5.43 mM) was added and the mixture stirred for 0.5 hours. Ethyl cyanoglyoxalate-2-oxime (0.77g, 5.43mM) was added and the mixture refluxed for 15 hours. After cooling, sodium ethoxide in ethanol (5.43mM) was added and the mixture refluxed for a further 2.5 hours. After cooling, the solid produced was removed by filtration. The filtrate was distilled at reduced pressure and the residue triturated with hot water. The solid residue was crystallised from methanol/methylene chloride (8:92). There was thus obtained 4-amino-6-hydroxy-5-nitroso-2-(2-phenyl)ethylpyrimidine (1.9g, 30% yield) NMR; DMSO- $d_6$ : 2.65-2.85 (m, 2H,  $CH_2-CH_2$ ), 2.85-3.1 (m, 2H,  $CH_2-CH_2$ ), 7.15-7.4 (m, 5H, aromatic-H), exchangeables under broad peaks.
- b) A mixture of 4-amino-6-hydroxy-5-nitroso-2-(2-phenyl)ethylpyrimidine (1.1g, 4mM), ethanol (15ml) and water (35ml) was heated to approx 60°C. Sodium dithionite was added slowly, portionwise until the green colour had disappeared. The mixture was then allowed to cool, concentrated to half the original volume, and cooled again. A pale beige precipitate was formed and was removed by filtration, washed with water, and dried. There was thus produced 4,5-diamino-6-hydroxy-2-(2-phenyl)ethylpyrimidine (0.7g, 70% yield). NMR; DMSO- $d_6$ : 2.6-2.8 (m, 2H,  $CH_2$ ), 2.8-3.05(m, 2H,  $CH_2$ ), 3.3-3.8 (b, 2H,  $NH_2$ ), 5.5(s, 2H,  $NH_2$ ), 7.1-7.4 (m, 5H, aromatic-H), 11.4-11.75 (b, 1H, OH).
- c) To a mixture of 4,5-diamino-6-hydroxy-2-(2-phenyl)ethylpyrimidine (0.55g, 2.39mM) and chloroform (40ml) under an argon atmosphere, was added triethylamine (365 $\mu$ l, 2.63mM) and then 2-furoyl chloride (258 $\mu$ l, 2.63mM) slowly over 0.25 hours. The mixture was stirred at ambient temperature for 15 hours. Water (50ml) was then added. The organic layer was separated, and the solvent removed by distillation under reduced pressure. There was thus produced 4-amino-5-(2-furanylcarbonyl)amino-6-hydroxy-2-(2-phenyl)ethyl pyrimidine (0.6g) as a solid; m.p. >240°C: NMR; DMSO- $d_6$ : 2.7 (m, 2H Ar- $CH_2$ ), 2.95(m, 2H,  $CH_2N$ ), 6.2 (s, 2H,  $NH_2$ ), 6.6 (m, 1H, furan-H), 7.3 (m, 1H, furan-H), 7.7(m, 5H, aromatic-H), 7.8 (m, 1H, furan-H), 8.7 (s, 1H, OH), 11.7 (b, 1H,  $NH-CO$ ).

#### EXAMPLE 16

A mixture of 7-ethoxy-5-methyl-2-(2-furyl)-oxazolo[5,4-d] pyrimidine (0.6g) and ethanol (saturated with ammonia) (20ml) in a sealed tube was heated in an autoclave at 120°C for 18 hours. After cooling, the solvent was distilled off under reduced pressure and the residue was purified by flash column chromatography, eluting with ethyl acetate/hexane (1:1), and was then further purified by flash column chromatography eluting with ammonia/methanol/methylene chloride (1.5:94). There was thus produced **7-amino-5-methyl-2-(2-furyl)-oxazolo[5,4-d]pyrimidine** (0.25g) m.p. 195-196°C; microanalysis, found: C, 55.2; H, 3.6; N, 25.6%;  $C_{10}H_8N_4O_2$  requires: C, 55.6; H, 3.7; N, 25.9%; NMR; DMSO- $d_6$ : 2.4 (s, 3H,  $CH_3$ ), 6.8(m, 1H, furan-H), 7.3 (d, 1H, furan-H), 7.55 - 7.75 (b, 2H,  $NH_2$ ), 8.0 (m, 1H, furan -H).

The starting material was prepared as follows:-

- a) A mixture of 5-carboxyethyl-4-ethoxy-2-(2-furyl)-oxazole (1.02g, 4mM) acetamide nitrate (0.53g, 4.4mM), sodium carbonate (475mg, 4.4mM) and acetonitrile (30ml) was heated at reflux for 4 hours. After cooling the mixture was concentrated. The residual syrup was dissolved in ethyl acetate and washed with dilute sodium hydroxide (3 x 50ml). The aqueous extracts were combined, acidified with dilute hydrochloric acid and cooled. The resultant solid was filtered, washed with water and dried. There was thus produced 4-ethoxy-5-(2-furanylcarbonyl)amino-6-hydroxy-2-methylpyrimidine (0.5g, 46% yield); microanalysis, found: C, 54.8; H, 5.1; N, 15.5%;  $C_{12}H_{13}N_3O_4$  requires: C, 54.8; H, 5.0; N, 16.0%.
- b) A mixture of 4-ethoxy-5-(2-furanylcarbonyl)amino-6-hydroxy-2-methylpyrimidine (2.07g, 7.87mM), phosphorus oxychloride (30ml) and dimethylaniline (1.5ml, 11.7mM) was heated at reflux for one hour. After cooling, the excess phosphorus oxychloride was removed by distillation under reduced pressure. Ethanol was then added, and the mixture partitioned between methylene chloride and water. The organic layer was separated, washed with sodium bicarbonate, water, dilute hydrochloric acid, water, and dried. The solvent was then removed by distillation under reduced pressure. Ethanol (10ml) was added and the solid filtered off. This solid was further purified by flash column chromatography eluting with ethyl acetate/hex-

ane (1:3). There was thus produced 7-ethoxy-5-methyl-2-(2-furyl)-oxazolo[5,4-d]pyrimidine (1.49g, 77% yield); m.p. 104-105.5°C.

#### EXAMPLE 17

5

A mixture of 5-amino-4-cyano-2-(2-furyl)oxazole (2.33g), cyanogen bromide (1.41g), potassium cyanide (0.86g), dimethylformamide (25ml) and potassium t-butoxide (1.8g) was stirred at 60°C for 3 hours. The solvent was distilled off under reduced pressure and the residue purified by flash column chromatography eluting with ethyl acetate/hexane (40:60). The resultant solid was recrystallised from ethyl acetate/hexane. There was thus obtained 7-amino-5-cyano-2-(2-furyl)-oxazolo-[5,4-d]pyrimidine (75mg); m.p. 260-262°C; microanalysis, found; C, 52.9; H, 2.2; N, 30.6%;  $C_{10}H_5N_5O_2$  requires; C, 52.9; H, 2.2; N, 30.8%.

#### EXAMPLE 18

15

A mixture of 5-amino-4-cyano-2-(2-furyl)oxazole (190mg, 1.1mM), formamidine acetate (1.1g, 11mM) and dimethylformamide (10ml) was heated at 100°C under an atmosphere of argon for twenty minutes. The solvent was removed by distillation under reduced pressure and ethanol (5ml) added to the residue. The solid was separated by filtration. There was thus obtained 7-amino-2-(2-furyl)oxazolo-[5,4-d]pyrimidine (0.19g) m.p. >250°C; microanalysis, found; C, 53.6; H, 2.8; N, 27.6%;  $C_9H_6N_4O_2$  requires; C, 53.5; H, 3.0; N, 27.7%.

20

#### EXAMPLE 19

25

A mixture of 2-[2-(3,4-dimethoxyphenyl)ethyl]amino-4,5,6-triaminopyrimidine (0.5g, 1.6mM), furyl-2-glyoxal (0.2g, 1.6mM), ethanol (20ml) and water (20ml) was warmed at 60°C for 0.5 hours. The solvents were removed by distillation under reduced pressure. The resultant syrup was purified by flash column chromatography eluting with methylene chloride containing slowly increasing amounts of methanol (0 - 6%). After removal of the solvent, a syrup was obtained and this was triturated with ethyl acetate and then methanol to give a solid. There was thus obtained 4-amino-2-[2-(3,4-dimethoxyphenyl)ethyl]amino-7-(2-furyl) pteridine (0.244g) m.p. 200 - 201°C; microanalysis, found; C, 60.8; H, 5.3; N, 20.6;  $C_{20}H_{20}N_6O_3 + 0.25 H_2O$  requires; C, 60.45; H, 5.2; N, 21.0%; NMR; DMSO- $d_6$ : 2.75-2.9 (t, 2H,  $CH_2-CH_2$ ), 3.5-3.7 (q, 2H,  $CH_2-NH$ ), 3.7-3.8 (d, 6H,  $OCH_3 \times 2$ ), 6.7-6.95(m, 4H, aromatic-H (x 3) + furan-H), 6.95 - 7.1 (b, 1H,  $NH$ ), 7.35 - 7.65 (m, 3H,  $NH_2$  + furan H), 8.0 (d, 1H, furan-H), 8.65 (s, 1H, pteridine-H); m/e  $[M+H]^+$  393.

30

#### EXAMPLES 20 - 22

35

The following compounds were prepared by a method similar to that described in Example 19, but using the appropriate triaminopyrimidine :-

#### EXAMPLE 20

40

4-amino-2-[2-(4-methoxyphenyl)ethyl]amino-7-(2-furyl)pteridine; m.p. 210 - 214°C (with decomposition); NMR; DMSO- $d_6$ : 2.75 - 2.95 (t, 2H,  $CH_2-CH_2$ ), 3.45 - 3.65 (q, 2H,  $CH_2-NH$ ), 3.7 (s, 3H,  $OCH_3$ ), 6.7 (m, 1H, furan-H), 6.8 - 6.9 (d, 2H, aromatic-H), 7.0 - 7.1 (b, 1H,  $NH$ ), 7.1 - 7.2 (d, 2H, aromatic-H), 7.35 - 7.5 (b, 1H, furan-H), 7.5 - 7.65 (b, 2H,  $NH_2$ ), 8.0 (s, 1H, furan-H), 8.65 (s, 1H, pteridine-H). m/e  $[M+H]^+$  363.

45

#### EXAMPLE 21

4-Amino-2-[2-(4-methylphenyl)ethyl]amino-7-(2-furyl)pteridine; m.p. 153-154°C; NMR; DMSO- $d_6$ : 2.3(s, 3H,  $CH_3$ ), 2.85-2.95(t, 2H,  $CH_2-CH_2$ ), 3.65-3.75(t, 2H,  $CH_2-NH$ ), 6.75(m, 1H, furan H), 7.1-7.25(q, 4H, aromatic-H), 7.5 (d, 1H, furan-H), 7.8-8.2 (b, 3H,  $NH_2$  + furan-H), 8.8 (s, 1H, pteridine-H); m/e  $[M+H]^+$  347.

50

#### EXAMPLE 22

4-Amino-2-methylthio-7-(2-furyl)pteridine. m.p. >250°C; NMR; DMSO- $d_6$ : 2.55 (s, 3H,  $SCH_3$ ), 6.8(m, 1H, furan-H), 7.6 (d, 1H, furan-H), 8.05 (m, 1H, furan-H), 8.1-8.25 (b, 2H,  $NH_2$ ), 9.0 (s, 1H, pteridine-H); m/e  $[M+H]^+$  260.

55

**EXAMPLE 23**

A mixture of 2-[2-(3,4-dimethoxyphenyl)ethyl]amino-4,5,6-triaminopyrimidine (1.0g, 3.2 mM), furyl-2-glyoxol (0.4g, 3.2mM), ethanol (30ml) and 2M sulphuric acid (30ml) was heated at 60°C for 1.5 hours. After cooling the solution was adjusted to PH 14 using dilute sodium hydroxide solution. The mixture was then extracted with ethyl acetate. The organic extracts were combined, dried, the solvent evaporated under reduced pressure. The resultant solid was triturated with methanol. There was thus produced 4-amino-2-[2-(3,4-dimethoxyphenyl)ethyl]amino-6-(2-furyl)-pteridine (0.85g) m.p. 178-180°C; microanalysis, found; C, 59.1; H, 4.9; N, 20.7%;  $C_{20}H_{20}N_6O_3 + 0.75 H_2O$  requires; C, 59.1; H, 5.17; N, 20.7; NMR: DMSO-d<sub>6</sub>; 2.75 - 2.9 (t, 2H, CH<sub>2</sub>-CH<sub>2</sub>), 3.5-3.7 (b, 2H, CH<sub>2</sub>-NH), 3.7 - 3.8 (d, 6H, OCH<sub>3</sub> x 2), 6.7 (m, 1H, furan-H), 6.7- 6.9 (m, 3H, aromatic-H), 7.1 (b, 1H, NH), 7.3 (d, 1H, furan-H), 7.5 - 7.7 (b, 2H, NH<sub>2</sub>), 7.85 (d, 1H, furan -H), 9.05 (s, 1H, pteridine-H); m/e [M+H]<sup>+</sup> 393.

**EXAMPLES 24 - 26**

The following compounds were prepared by a method similar to that described in Example 23 but using the appropriate triaminopyrimidine:-

**EXAMPLE 24**

Preparation worked up without basification. There was thus produced 4-amino-2-[2-(4-methylphenyl)ethyl]amino-6-(2-furyl)pteridine m.p. 246-248°C (with decomposition); microanalysis, found; C, 46.2; H, 4.0; N, 16.4; S, 9.8%;  $C_{19}H_{18}N_6O + 1.5H_2SO_4$  requires; C, 46.2; H, 4.3; N, 17.0; S, 9.8%; NMR: DMSO-d<sub>6</sub>; 2.3(s, 3H, CH<sub>3</sub>), 2.8 - 2.95(m, 2H, CH<sub>2</sub> - CH<sub>2</sub>), 3.6-3.8 (b, 2H, CH<sub>2</sub>NH), 6.8 (m, 1H, furan-H), 7.05- 7.25(m, 4H, aromatic-H), 7.5 (d, 1H, furan-H), 7.9-8.0 (b, 1H, furan-H) , 8.8 - 9.0 (b, 1H, NH), 9.2 (b, 1H, pteridine-H), 9.25 - 9.6 (b, 2H, NH<sub>2</sub>). m/e [M+H]<sup>+</sup> 347.

**EXAMPLE 25**

4-Amino-2-[2-(4-methoxyphenyl)ethyl]amino-6-(2-furyl)pteridine; m.p. 212-214°C; NMR: DMSO-d<sub>6</sub>; 2.75-2.9 (t, 2H, CH<sub>2</sub>-CH<sub>2</sub>), 3.45-3.6 (q, 2H, CH<sub>2</sub>NH), 3.7 (s, 3H, OCH<sub>3</sub>), 6.7 (m, 1H, furan-H), 6.6-6.7 (d, 2H, aromatic-H), 7.1 (b, 1H, NH), 7.15 - 7.25 (d, 2H, aromatic-H), 7.3 (d, 1H, furan-H), 7.5 - 7.7 (b, 2H, NH<sub>2</sub>), 7.85 (m, 1H, furan-H), 9.05 (s, 1H, pteridine-H). m/e [M+H]<sup>+</sup> 363.

**EXAMPLE 26**

4-Amino-2-methylthio-6-(2-furyl)-pteridine; m.p. 200°C; microanalysis, found; C, 49.5; H, 3.6; N, 25.7%;  $C_{11}H_9N_5O S (0.5H_2O)$  requires; C, 49.3; H, 3.7; N, 26.1%; NMR: DMSO-d<sub>6</sub>; 2.55 (s, 3H, SCH<sub>3</sub>), 6.75 (m, 1H, furan-H), 7.5 (d, 1H, furan-H), 7.95 (d, 1H, furan-H) 8.1-8.4 (b, 2H, NH<sub>2</sub>), 9.3 (s, 1H, pteridine-H).

**EXAMPLE 27**

The following illustrate representative pharmaceutical dosage forms containing a compound of formula I, for example as illustrated in any of the previous Examples, (hereafter referred to as "compound X"), for therapeutic or prophylactic use in humans:-



EP 0 544 445 A2

(a) Tablet	mg/tablet
Compound X	50
Lactose Ph.Eur	223.75
Croscarmellose sodium	6.0
Maize starch	15.0
Polyvinylpyrrolidone (5% w/v paste)	2.25
Magnesium stearate	3.0
(b) Capsule	mg/capsule
Compound X	10
Lactose Ph.Eur	488.5
Magnesium stearate	1.5


The above formulations may be obtained by conventional procedures well known in the pharmaceutical art. The tablets may be enteric coated by conventional means, for example to provide a coating of cellulose acetate phthalate.

## CHEMICAL FORMULAE

5

10

15




I

20

25

30




III

35

40


45




V

50


55



II



IV





VI

CHEMICAL FORMULAE  
(continued)

5

10



15



20

25

30





35

40

45

50



55

Claims

1. A compound of the formula I (set out hereinafter in the final part of these claims) wherein:

R<sup>1</sup> is hydrogen, (1-6C)alkyl, or (1-4C)alkanoyl;

R<sup>2</sup> is hydrogen, cyano or a group of formula R<sup>3</sup>X;

R<sup>3</sup> (when not as hereinbelow defined together with X) is (3-12C)cycloalkyl, (3-6C)alkenyl, phenyl(3-6C)alkenyl, 5- or 6-membered heteroaryl, optionally substituted (1-6C)alkyl or optionally substituted phenyl, said optionally substituted alkyl being unsubstituted or substituted by one of (3-6C)cycloalkyl, optionally substituted 5- or 6-membered heteroaryl, optionally substituted phenyl and a group of formula R<sup>4</sup>(CO)<sub>n</sub>X<sub>a</sub>(CO)<sub>m</sub> in which R<sup>4</sup> is (1-6C)alkyl, (3-6C)cycloalkyl, optionally substituted phenyl or optionally substituted phenyl(1-4C)alkyl, n and m are each 0 or 1, provided that n+m is 0 or 1, and that when m is 0, X and X<sub>a</sub> are separated by at least two carbon atoms, X<sub>a</sub> is oxy, thio, sulphinyl, sulphonyl or an imino group of formula -NR<sup>b</sup> in which R<sup>b</sup> is hydrogen, (1-6C)alkyl or together with R<sup>4</sup> and the adjacent nitrogen atom forms a 4 to 6-membered saturated heterocyclic ring, said optionally substituted 5- or 6-membered heteroaryl being unsubstituted or substituted by 1 or 2 of (1-4C)alkyl, (1-4C)alkoxy and halogeno, and any of said optionally substituted phenyl being unsubstituted or substituted by (1-4C)alkylenedioxy or by 1, 2 or 3 of halogeno, cyano, trifluoromethyl, (1-4C)alkoxycarbonyl, hydroxy, hydroxymethyl, amino, (1-4C)alkanoylamino, (1-4C)alkoxymethyl, (1-4C)alkanoyloxy, benzyloxy, halogenobenzyloxy, (1-4C)alkylsulphonylamino, (1-4C)haloalkylsulphonylamino, nitro, and (1-4C)alkyl or alkoxy optionally bearing a group of formula R<sup>5</sup>CO in which R<sup>5</sup> is (1-4C)alkoxy, (3-6C)alkylamino, (3-6C)cycloalkylamino or (N-(1-4C)alkyl) (N-(1-4C)dialkylamino(1-4C)alkyl)amino, and sulphamoyl of formula -SO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup> in which R<sup>6</sup> and R<sup>7</sup> are independently hydrogen or (1-4C)alkyl, or R<sup>6</sup> is hydrogen and R<sup>7</sup> is ((2-5C)alkoxycarbonyl)(CH<sub>2</sub>)<sub>q</sub>, carbamoyl(CH<sub>2</sub>)<sub>q</sub> or (N-(1-4C)alkylcarbamoyl)(CH<sub>2</sub>)<sub>q</sub>, in which q is 0 or an integer of from 1 to 4, or R<sup>6</sup> is (1-4C)alkyl and R<sup>7</sup> is di(1-4C)alkylamino(1-4C)alkyl; and X is a direct bond or oxy, thio, sulphinyl, sulphonyl or an imino group of formula -NRA- in which R<sub>a</sub> is hydrogen, (1-6C)alkyl or together with R<sup>3</sup> and the adjacent nitrogen atom forms a 4 to 6-membered saturated heterocyclic ring;

A is -N=CQ-O-, -N=CQ-NR<sup>8</sup>-, -N=CQ-CH=N- or -N=CH-CQ=N-;

Q is 2-furyl; and

R<sup>8</sup> is hydrogen or (1-4C)alkyl;

provided that when R<sup>1</sup> and R<sup>2</sup> are hydrogen and A is -N=CQ-NR<sup>8</sup>-, R<sup>8</sup> is not hydrogen; or a pharmaceutically acceptable salt thereof.

2. A compound as claimed in claim 1, in which R<sup>1</sup> is hydrogen.
3. A compound as claimed in claim 1, in which said 5- or 6-membered heteroaryl represented by R<sup>3</sup> is selected from pyridyl, isoxazolyl and thiadiazolyl, and the 5- or 6-membered heteroaryl in said optionally substituted 5- or 6-membered heteroaryl is selected from furyl, pyridyl and thienyl.
4. A compound as claimed in claim 1 or claim 2, in which R<sup>2</sup> is hydrogen, cyano or R<sup>3</sup>X in which R<sup>3</sup> is (1-4C)alkyl, (3-6C)alkenyl, pyridyl(1-4C)alkyl or phenyl(1-4C)alkyl optionally substituted on the phenyl moiety by 1 or 2 of halogen, hydroxy, (1-4C)alkanoyloxy, (1-4C)alkyl and (1-4C)alkoxy; and X is a direct bond, oxy, thio or NH.
5. A compound as claimed in claim 4, in which R<sup>2</sup> is 4-chlorobenzyl, 2-phenylethyl, 2-phenylethylamino, 2-(4-hydroxyphenyl)ethylamino, 2-(4-methylphenyl)ethylamino, 2-(4-methoxyphenyl)ethylamino or 2-(3,4-dimethoxyphenyl)ethylamino.
6. A compound as claimed in any one of claims 1 to 5, in which R<sup>8</sup> is hydrogen or methyl.
7. A compound as claimed in claim 1, in which
 

R<sup>1</sup> is hydrogen;

R<sup>2</sup> is R<sup>3</sup>X

R<sup>3</sup> is (1-4C)alkyl, (3-6C)alkenyl, pyridyl(1-4C)alkyl or phenyl(1-4C)alkyl optionally substituted on the phenyl moiety by 1 or 2 of halogen, hydroxy, (1-4C)alkanoyloxy, (1-4C)alkyl and (1-4C)alkoxy;

X is a direct bond, oxy, thio or NH;







A is -N=CQ-O-, -N=CQ-NR<sup>8</sup>-, -N=CQ-CH=N- or -N=CH-CQ=N-;

Q is 2-furyl; and



R<sup>8</sup> is hydrogen or methyl.
8. A process for the preparation of a compound as defined in claim 1, which comprises

- (a) reacting a compound of formula II in which Z<sup>1</sup> is a suitable leaving group with a compound of formula R<sup>1</sup>NH<sub>2</sub>,
- (b) reacting a compound of formula III or a salt thereof with a compound of formula IV or a salt thereof, in which either R<sup>9</sup> is a leaving group and X<sup>1</sup> is O or NH, or R<sup>9</sup> is CHO and X<sup>1</sup> is NH, and X<sup>2</sup> is O, S or NH,
- (c) for a compound of Formula I which A is -N=CQ-O- or -N=CQ-NR<sup>8</sup>- cyclising a compound of formula V in which one of R<sup>10</sup> and R<sup>11</sup> is hydrogen and the other is a group of formula C(=X<sup>4</sup>)Q in which X<sup>3</sup> is O or NH, and X<sup>4</sup> is O, S or NH,
- (d) for a compound of formula I in which A is -N=CQ-NR<sup>8</sup>- and R<sup>8</sup> is (1-4C)alkyl, reacting a corresponding compound of formula I in which R<sup>8</sup> is hydrogen with an appropriate alkylating agent,
- (e) reacting a compound of formula VI with an amidine of formula VII or, for a compound where R<sup>2</sup> is cyano, a cyanogen halide and an alkali metal cyanide, or
- (f) for a compound of formula I in which X is O, S or NR<sub>a</sub>, reacting a compound of formula VIII in which Z<sup>2</sup> is a leaving group with a compound of formula R<sup>3</sup>XH or a salt thereof,
- whereafter, when a compound of formula I in which R<sup>1</sup> is (1-6C)alkyl or (1-4C)alkanoyl is desired, if necessary alkylating or acylating a corresponding compound of formula I in which R<sup>1</sup> is hydrogen;
- when a pharmaceutically acceptable salt is required, obtaining it by reacting a compound of formula I with the appropriate acid or base affording a physiologically acceptable ion or by any other conventional procedure; and
- when an optically active form of a chiral compound of formula I is required, either carrying out one of processes (a) to (f) above using the appropriate optically active starting material or else resolving a racemic form by a conventional procedure; and
- wherein in which R<sup>1</sup>, R<sup>2</sup>, X, A and Q have any of the meanings given in claim 1.
9. A pharmaceutical composition, which comprises a compound of formula I or a pharmaceutically acceptable salt thereof as defined in claim 1, in a mixture or together with a pharmaceutically acceptable diluent or carrier.
10. A compound of the formula II or VIII in which R<sup>2</sup> and A have any of the meanings given in claim 1, Z<sup>1</sup> is chloro or bromo and Z<sup>2</sup> is (1-4C)alkylsulphonyl.

CHEMICAL FORMULAE



CHEMICAL FORMULAE



```

      ##          #      ##
      #          #
##  #  #  #  # #####  ###      #      #####  ###  ###
  ##  ##  #  #  #      #      #      #      #      #
  #  #  #  #####      #      #      #####      #  #
  #  #  #  #  #      #      #      #      #      #
  #  #  #  #  #      #      #      #      #      #
#####  ##  #  ##  #####  #####      #####      #
                                     #
                                     #
                                     ###

```

Job : 166  
 Date: 4/6/2007  
 Time: 12:50:42 PM





Publication number : **0 574 906 A2**

**EUROPEAN PATENT APPLICATION**

Application number : **93109664.8**

Date of filing : **17.06.93**

Int. Cl.<sup>5</sup> : **C07D 239/50, C07D 403/04,  
 C07D 475/08, C07D 239/86,  
 C07D 237/14, A61K 31/525,  
 A61K 31/50, A61K 31/505**

Priority : **17.06.92 HU 922021**

Date of publication of application :  
**22.12.93 Bulletin 93/51**

Designated Contracting States :  
**BE CH DE DK FR GB IT LI NL SE**

Applicant : **NISSHIN FLOUR MILLING CO.,  
 LTD.  
 19-12, Nihonbashi-koamicho  
 Chuo-ku, Tokyo (JP)**


Inventor : **Zubovics, Zoltán Dr.  
 1 Berzeviczy u.  
 H-1042 Budapest (HU)  
 Inventor : **Goldschmidt née Horváth, Katalin  
 Dr.  
 54/b Nagybányai ut  
 H-1025 Budapest (HU)  
 Inventor : **Szilágyi née Farago, Katalin Dr.  
 66/a Szakasits A. ut  
 H-1115 Budapest (HU)  
 Inventor : **Ferenc, András Dr.  
 69 Kutvölgyi ut  
 H-1125 Budapest (HU)********

Inventor : **Hodula née Szentkuti, Eszter Dr.  
 5/b Bihari ut  
 H-1107 Budapest (HU)  
 Inventor : **Toldy, Lajos Dr.  
 53 Villányi ut  
 H-1118 Budapest (HU)  
 Inventor : **Sutka, Klára Dr.  
 6 Vizimolnár u.  
 H-1031 Budapest (HU)  
 Inventor : **Fittler, Zsuzsanna  
 35 Szentkirályi u.  
 H-1088 Budapest (HU)  
 Inventor : **Sebestyén, László  
 44 Körakáspark  
 H-1157 Budapest (HU)  
 Inventor : **Görgényi née Kiss, Katalin Dr.  
 42 Gábor A. u.  
 H-1026 Budapest (HU)  
 Inventor : **Sziráki, István Dr.  
 12 Báthori u.  
 H-1054 Budapest (HU)  
 Inventor : **Gyimesi, József Dr.  
 10 Szent István park  
 H-1137 Budapest (HU)  
 Inventor : **Vitkoczi née Kardos, Valéria  
 7 Hevesi Gy.u.  
 H-1157 Budapest (HU)******************

Representative : **Türk, Gille, Hrabal, Leifert  
 Brucknerstrasse 20  
 D-40593 Düsseldorf (DE)**

**(54) Piperazine and homopiperazine derivatives, pharmaceutical compositions containing them and process for preparing the same.**

**(57) The lipid peroxidation inhibiting piperazine and homopiperazine derivatives of the general formula (I) and the pharmaceutically acceptable acid addition salts thereof,**



Lip stands for hydrogen; C<sub>15-20</sub> alkyl; C<sub>10-20</sub> alkanoyl or C<sub>10-20</sub> alkenoyl; trityl optionally substituted by halogen; adamantyl; 1- or 2-naphthyloxy or oxo-substituted tetrahydronaphthyloxy; or an amine protective group commonly used e.g. in the peptide chemistry;


EP 0 574 906 A2

A<sup>1</sup> and A<sup>2</sup> are selected independently from the group consisting of a single bond and C<sub>2-3</sub> alkylene optionally substituted by hydroxy or oxo ;

n is 1 or 2 ; and

Het represents

a group of the general formula (a),




(a)

wherein


R<sup>1</sup> is amino or 1-pyrrolidinyl ;

or a 4-chloro-3-oxo-2,3-dihydro-5-pyridazinyl group of the formula (b) ;




(b)

or a 4-amino-6,7-dimethoxy-2-quinazolinyl group of the formula (c) ;




(c)

or a 4,7-diamino-6-phenyl-2-pteridiny group of the formula (d) ;




(d)

or a 2,7-diamino-6-phenyl-4-pteridiny group of the formula (e) ;




(e)

or a 2,4,7-triamino-6-pteridiny carbonyl group of the formula (f) ;



(f)

or a group of the general formula (g);



wherein

X means oxygen, sulfur or nitrogen optionally substituted by lower alkyl,

with the first proviso that

when Het stands for a group of the general formula (a) and both A<sup>1</sup> and A<sup>2</sup> mean single bonds then Lip may not be hydrogen;

with the second proviso that

when Lip is different from naphthyloxy or oxo-substituted tetrahydronaphthyloxy then A<sup>1</sup> means a single bond;

with the third proviso that

when Lip represents naphthyloxy or oxo-substituted tetrahydronaphthyloxy then A<sup>1</sup> may not be a single bond, as well as with the fourth proviso that

A<sup>1</sup> and A<sup>2</sup> cannot simultaneously stand for C<sub>2-3</sub> alkylene optionally substituted by hydroxy or oxo.

The present invention relates to novel piperazine and homopiperazine derivatives possessing lipid peroxidation inhibitory activity, pharmaceutical compositions containing these compounds and process for their preparation.

It is known that the peroxidation of lipids in the living organism is a metal ion catalysed radical process playing an important role in a number of pathological conditions and diseases as well as in ageing. Such diseases and conditions related to the peroxidation of lipids are e.g. the injury of the brain and spinal cord, stroke, certain types of cerebrovascular spasms, tissue damages arising from ischemia (especially the so-called reperfusion injuries occurring during and after restoration of blood flow), furthermore myocardial infarction, atherosclerosis, inflammatory diseases, e.g. rheumatoid arthritis, various autoimmune diseases, drug toxicity, asthma and the like [see e.g. B. Halliwell, *FASEB J.* **1**, 358 (1987) and J.M.C. Gutteridge and B. Halliwell, *Methods in Enzymology* **186**, 1 (1990)].

An intensive research is being carried out worldwide to find on one hand substances which inhibit generally the oxidation processes in the living organism (antioxidants) while on the other hand to discover active agents specifically inhibiting the peroxidation of lipids. Compounds exerting the latter type of activity can be used in mammals, including man, for the prevention and/or treatment of diseases and conditions such as those mentioned above as being related to lipid peroxidation processes. Such drugs may have an outstanding therapeutic importance and active agents that can be used e.g. for the treatment of injuries of the central nervous system can be considered as life-saving medicaments.

Several endogenous substances inhibiting lipid peroxidation are present in the internal regulatory system of the mammalian organism, one of which is  $\alpha$ -tocopherol, i.e. vitamin E [see e.g. M. J. Kelly in "Progress in Medicinal Chemistry" Vol. 25, p. 250, ed.: G. P. Ellis and G. B. West, Elsevier Science Publishers, 1988].

The objective of the present invention was to develop novel piperazine and homopiperazine derivatives being capable to effectively inhibit lipid peroxidation and as such, being useful for the treatment of various diseases and conditions of mammals, including man, where inhibition of lipid peroxidation is desirable.

Surprisingly, it was found that this requirement is met in an outstanding manner by certain piperazine and homopiperazine derivatives bearing a six-membered nitrogen heterocycle, e.g. a substituted pyrimidine or a similar condensed heterocycle, such as a phenylpteridine which heterocycle can be bound directly or through a lower alkylene chain to one of the piperazine (or homopiperazine) nitrogen atoms while a hydrocarbyl group such as those exemplified below (or occasionally hydrogen) can be attached to the other nitrogen of the piperazine (or homopiperazine) ring. Numerous compounds have been described in the literature which consist of the above three types of structural units, i.e. an open chain or cyclic hydrocarbyl group, a piperazine ring and a substituted nitrogen heterocycle.

Such compounds show various biological effects. One of these important classes of compounds includes molecules wherein the nitrogen heterocycle mentioned above, e.g. a pyridine or pyrimidine ring substituted by amino groups as well as the hydrocarbyl group has been varied in a wide range. Thus the hydrocarbyl group may be e.g. a steroid skeleton (published PCT applications Nos. WO 87/01706 and WO 87/07895), a seco-steroid (published PCT-application No. WO 88/07527) or various substituted alkyl groups of medium chain length, various mono and bicycles, e.g. a substituted phenyl, phenoxyalkyl, benzopyranyl and the like (published PCT application WO 88/08424). These classes of compounds were claimed to possess lipid peroxidation inhibitory activity. It should be noted that no such molecules bearing an alkenyl, alkanoyl, alkenoyl or an alkyl of more than 14 carbon atoms are disclosed.

In an other large group of compounds containing the three characteristic structural elements mentioned above, various types of hydrocarbyl groups being either similar to or different from those mentioned above are present, together with the nitrogen heterocycles which latter are nearly identical to those discussed in the preceding paragraph. Thus e.g. phenyl, benzyl and benzhydryl [French patent specification No. 1,507,062, published German patent applications Nos. 1,947,332 and 2,211,738, Belgian patent specification No. 739,283 and Canadian patent specification No. 983,497 as well as the published Japanese patent application (Kokai) No. 74/76887], benzodioxolyl and benzodioxanyl [Canadian patent specifications Nos. 979,894, 983,493, 983,494 and 983,495 ; and the published Japanese patent applications (Kokai) Nos. 74/72270, 74/72271, 74/72272 and 74/72273], further a 3-trityl-n-propylgroup [G. L. Regnier et al., *J. Med. Chem.* **15**, 295 (1972)] occur as characteristic structural elements. (It should be noted that no derivatives containing naphthylalkoxyalkyl, trityl or adamantyl attached to the piperazine nitrogen are mentioned among the above compounds.) A high number of the latter compounds has been described to show various biological effects (such as vasodilatory, sedative, analgetic, antiinflammatory and respiration promoting effects), an eventual lipid peroxidation inhibitory activity has, however, never been mentioned.


In addition to the above classes of compounds containing a piperazine ring and a further nitrogen heterocycle several other types of compounds have been published to inhibit the peroxidation of lipids. In the following some examples are given : cyclic hydroxamic acids [Y. Teshima et al., *J. Antibiot.* **44**, 685 (1991)]; pyrimidine-

diones (published European patent application No. 447,324); acylamino-7-hydroxyindane derivatives [Y. Oshiro et al., J. Med. Chem. **34**, 2014 (1991)]; amino analogues of vitamin C (published European patent applications Nos. 446,539 and 447,325); monocyclic analogues of vitamin E (Japanese patent specification No. 01,226,843); 4-arylthiopiperidine derivatives (published European patent application No. 433,167); 1,4-benzoquinones [e.g. G. Goto, et al. Chem. Pharm. Bull. **33**, 4422 (1985)]; carboxyalkyl and hydroxyalkyl naphthoquinones [K. Okamoto et al., Chem. Pharm. Bull. **30**, 2797 (1982)]; selenium compounds [A. Muller et al., Biochem. Pharmacol. **33**, 3235 (1984) and A.L. Tappel, Fed. Proc. **24**, 73 (1965)]; curcuminoids [S. Toda et al., J. Ethnopharmacology. **23**, 105 (1988)]; quinazoline derivatives (published European patent application No. 302,967); pyridylquinolines (published European patent application No. 289,365); dihydroquinoline derivatives [A. Blazovics et al., Free Radical Res. Commun. **4**, 409 (1988)]; anthron and acridine derivatives [P. Frank, Biochem. Biophys. Res. Commun. **140**, 797 (1986)]; dihydropyridinethiones [A. G. Odynets et al., Eksp. Med. (Riga) **21**, 127 (1986); Chem. Abstr. **106**, 148956]; pyrazolone derivatives (Japanese patent specification No. 62,149,617); benzothiazines (Japanese patent specification No. 01,287,077); flavonoids (see e.g. R. Campos et al., Planta Med. **55**, 417 (1989)]; pyrimidopyrimidines [I. Bellido et al., Meth. Find. Exp. Clin. Pharmacol. **13**, 371 (1991)]; methylated uric acid analogues [Y. Nishida, J. Pharm. Pharmacol. **43**, 885 (1991)]; methylprednisolone [see e.g. H. B. Demopoulos et al., Can. J. Physiol. Pharmacol. **60**, 1415 (1982)]; dehydroalanine derivatives [P. Buc-Calderon et al., Arch. Biochem. Biophys. **273**, 339 (1989)]; acylated polyamines [J. M. Braughler et al., Biochem. Pharmacol. **37**, 3853 (1988)].

The literature data cited above illustrate that the compounds containing a mono or diamino substituted nitrogen heterocycle attached to a piperazine ring do not necessarily inhibit lipid peroxidation and, on the other hand, the presence of the above nitrogen heterocycles is not imperative for the same biological activity.

As referred to above the desired lipid peroxidation inhibitory activity is shown also by certain novel piperazine derivatives wherein a phenylpteridine ringsystem is attached, optionally through an alkylene chain to one of the nitrogen atoms in a piperazine ring; in the most preferable compounds of this type the other nitrogen is unsubstituted.

The Belgian patent specification No. 901,850 and the published German patent application No. 2,700,073 disclose compounds of the general formula (A)




(A)

wherein R stands for a substituted amino and Alk means an optionally substituted alkylene chain. In these compounds R may be e.g. mono or dialkylamino, benzylamino or a five or six-membered heterocyclic group optionally containing one or two additional heteroatoms such as morpholinyl, piperidinyl, pyrrolidinyl or 4-methyl-1-piperazinyl. These patent specifications do not describe compounds containing piperazinyl groups being unsubstituted or substituted with a group other than methyl in position 4 as R. It has been published in the above two patent specifications as well as in papers [see e.g. H. Priewer et al., Arzneim.-Forsch./Drug Res. **35**, 1819 (1985); Pharm. Res. **3**, 102 (1986); Drugs of the Future **11**, 669 (1986)] that the above compounds possess diuretic, potassium retaining, calcium antagonist and cardioprotective activities, but an eventual lipid peroxidation inhibitory activity was not mentioned.

In the lipid peroxidation inhibitory novel piperazine and homopiperazine derivatives of the present invention a six-membered, optionally substituted heterocycle containing two nitrogen atoms and being optionally condensed with a benzene or pyrazine ring (such as a pyrimidine, pyridazine, quinazoline or pteridine) is attached, optionally through an alkylene chain, to one of the nitrogen atoms in a piperazine (or homopiperazine) ring, while a long, open-chain hydrocarbyl group, a moiety containing two, optionally partially saturated condensed carbocycles (e.g. naphthyl) connected via an oxygen atom and a lower alkylene chain, a methyl group bearing three noncondensed unsaturated carbocycles (e.g. trityl) or a moiety consisting of three condensed saturated carbocycles (adamantyl) may be bound to the other nitrogen atom in the piperazine (or homopiperazine) ring; or the latter nitrogen may also be unsubstituted.

Accordingly, the present invention provides compounds of the general formula (I)



wherein


Lip stands for hydrogen; C<sub>15-20</sub> alkyl; C<sub>10-20</sub> alkanoyl or C<sub>10-20</sub> alkenoyl; trityl optionally substituted by halogen; adamantyl; 1- or 2-naphthoxy or oxo-substituted tetrahydronaphthoxy; or an amine protective group commonly used e.g. in the peptide chemistry;

A<sup>1</sup> and A<sup>2</sup> are selected independently from the group consisting of a single bond and C<sub>2-3</sub> alkylene optionally substituted by hydroxy or oxo;

n is 1 or 2; and

Het represents


a group of the general formula (a),




wherein

R<sup>1</sup> is amino or 1-pyrrolidinyl;


or a 4-chloro-3-oxo-2,3-dihydro-5-pyridazinyl group of the formula (b);



or a 4-amino-6,7-dimethoxy-2-quinazolinyl group of the formula (c);




or a 4,7-diamino-6-phenyl-2-pteridiny group of the formula (d);




(d)

or a 2,7-diamino-6-phenyl-4-pteridiny group of the formula (e);




(e)

or a 2,4,7-triamino-6-pteridiny carbonyl group of the formula (f);



(f)

or a group of the general formula (g);



(g)

wherein

- X means oxygen, sulfur or nitrogen optionally substituted by lower alkyl,
- with the first proviso that
- when Het stands for a group of the general formula (a) and both A<sup>1</sup> and A<sup>2</sup> mean single bonds then Lip may not be hydrogen;
- with the second proviso that
- when Lip is different from naphthyloxy or oxo-substituted tetrahydronaphthyloxy then A<sup>1</sup> means a single bond;
- with the third proviso that
- when Lip represents naphthyloxy or oxo-substituted tetrahydronaphthyloxy then A<sup>1</sup> may not be a single bond, as well as with the fourth proviso that
- A<sup>1</sup> and A<sup>2</sup> cannot simultaneously stand for C<sub>2-3</sub> alkylene optionally substituted by hydroxy or oxo, as well as their pharmaceutically acceptable acid addition salts and pharmaceutical compositions containing these compounds.

According to another aspect of the invention, there is provided a process for the preparation of the novel

compounds of the general formula (I) and the pharmaceutically acceptable salts thereof.

Due to their lipid peroxidation inhibitory effect, preferred are the compounds of the general formula (I), wherein

Lip means an open-chain or cyclic lipophilic group, e.g. a C<sub>10-20</sub> alkenoyl, o-chlorotriptyl, 1- or 2-naphthyloxy;

A<sup>1</sup> represents a single bond, 2-hydroxy-1,3-propylene or CH<sub>2</sub>CO;

A<sup>2</sup> is a single bond;

n is 1 or 2; and

Het means a group of the general formula (a).

Similarly, by virtue of their lipid peroxidation inhibitory effect, preferred are the compounds of the general formula (I), wherein

Lip means hydrogen;

A<sup>1</sup> is a single bond;

A<sup>2</sup> represents 1,3-propylene optionally substituted by hydroxy;

or ethylene optionally substituted by oxo;

n is 1 or 2; and

Het stands for a group of the general formula (g),


wherein

X is as defined above.

Certain compounds of the general formula (I), wherein Lip means an amine protective group being commonly used in peptide chemistry, are also advantageous since they are useful intermediates in the synthesis of other compounds of the general formula (I).

The pharmaceutically acceptable acid addition salts of the compounds of the general formula (I) are salts formed with the usual known, non-toxic organic or inorganic acids, such salts include the hydrochlorides, sulfates, phosphates, tartrates, fumarates, citrates and the like.

The compounds of the present invention can be prepared by using various methods known per se. These methods differ from each other in the order of coupling of the individual structural elements of the compounds of the invention, i.e. Lip, the piperazine (or homopiperazine) ring and Het. Thus, according to the invention, the compounds of the general formula (I),



wherein Lip, A<sup>1</sup>, n, A<sup>2</sup> and Het are as defined above and their pharmaceutically acceptable acid addition salts can be prepared by the following methods:

a) for preparing compounds of the general formula (I), wherein

Lip is as defined in the introduction, with the proviso that it may not be hydrogen or an amine protective group;

A<sup>1</sup> is as defined in the introduction, with the proviso that when Lip stands for naphthyloxy or oxo-substituted tetrahydronaphthyloxy then it may not be a single bond; and

n, A<sup>2</sup> and Het are as defined in the introduction,

a compound of the general formula (II),




wherein

Lip and A<sup>1</sup> are as defined above and

L<sup>1</sup> is a leaving group,


is reacted with a compound of the general formula (III),






wherein

- n, A<sup>2</sup> and Het are as defined above; or  
 b) for preparing compounds of the general formula (I), wherein  
 Lip means naphthyloxy or oxo-substituted tetrahydronaphthyloxy;  
 A<sup>1</sup> stands for 1,3-propylene substituted by hydroxy; and  
 n, A<sup>2</sup> and Het are as defined in the introduction,  
 a compound of the general formula (IV),




wherein

Lip is as defined above,  
 is reacted with a compound of the general formula (III),



wherein

- n, A<sup>2</sup> and Het are as defined above; or  
 c) for preparing compounds of the general formula (I), wherein  
 Lip is as defined in the introduction, with the proviso that it may not be hydrogen;  
 A<sup>1</sup> is as defined in the introduction, with the proviso that when Lip stands for naphthyloxy or oxo-substituted tetrahydronaphthyloxy then A<sup>1</sup> may not be a single bond; and with the other proviso that when Lip stands for an amine protective group then A<sup>1</sup> is a single bond; and  
 n, A<sup>2</sup> and Het are as defined in the introduction,  
 a compound of the general formula (V),



wherein

Lip, A<sup>1</sup> and n are as defined above,  
 is reacted with a compound of the general formula (VI),  
 L<sup>2</sup>A<sup>2</sup>-Het  
 (VI)

wherein

$A^2$  and  $Het$  are as defined above, and

**L<sup>2</sup> stands for a leaving group; or**

d) for preparing compounds of the general formula (I), wherein


**5 Lip** means naphthylxy or oxo-substituted tetrahydronaphthylxy;

$A^1$  is as defined in the introduction, with the proviso that it may not be a single bond; and

n, A<sup>2</sup> and Het are as defined for formula (I),

a compound of the general formula (VII),

**10**



wherein

$A^1$ ,  $n$ ,  $A^2$  and  $Het$  are as defined above, and

20  $L^1$  stands for a leaving group,

is reacted with a compound of the general formula Lip-H,

wherein

**Lip** is as defined above; or


e) for preparing compounds of the general formula (I), wherein

25 Lip is as defined in the introduction, with the proviso that it may not be naphthyloxy or oxo-substituted tetrahydronaphthyloxy;

**A<sup>1</sup> is a single bond;**

Het stands for a group of the general formula (g),

30




wherein

40 X is as defined in the introduction; and

$n$  and  $A^2$  are as defined above,

a compound of the general formula (VIII),

45




wherein

Lip is as defined above, with the proviso that it may not be hydrogen, naphthyl or oxo-substituted tetrahydronaphthyl;

55 X means oxygen, sulfur or nitrogen optionally substituted by lower alkyl; and

$n$  and  $A^2$  are as defined above,

is reacted with 5-nitroso-2,4,6-triaminopyrimidine of the formula (IX),



(IX)


and in the case when Lip stands for an amine protective group, this protective group is removed from the compound thus obtained; or

f) for preparing compounds of the general formula (I), wherein

Lip is as defined in the introduction, with the proviso that it may not be naphthyloxy or oxo-substituted tetrahydronaphthyloxy;


both A<sup>1</sup> and A<sup>2</sup> are single bonds;

Het stands for a group of the formula (d);



(d)

and n is as defined in the introduction,  
a compound of the general formula (X),



(X)

wherein

Lip is as defined above, with the proviso that it may not be hydrogen, naphthyloxy or oxo-substituted tetrahydronaphthyloxy; and

n is as defined above,

is reacted with benzyl cyanide and in the case when Lip stands for an amine protective group, this protective group is removed from the product thus obtained; or


g) for preparing compounds of the general formula (I), wherein

Lip is as defined in the introduction, with the proviso that it may not be naphthyloxy or oxo-substituted tetrahydronaphthyloxy;

both A<sup>1</sup> and A<sup>2</sup> are single bonds;

Het stands for a group of the formula (e);

5




(e)

10

and n is as defined in the introduction,  
a compound of the general formula (XI),

15



20

25

(XI)

wherein

30

Lip is as defined above, with the proviso that it may not be hydrogen, naphthyloxy or oxo-substituted tetrahydronaphthyloxy; and

n is as defined above,

is reacted with benzyl cyanide and in the case, when Lip stands for an amine protective group, this protective group is removed from the product obtained; or

h) for preparing compounds of the general formula (I), wherein


35

Lip is as defined in the introduction, with the proviso that it may not be naphthyloxy or oxo-substituted tetrahydronaphthyloxy;

both A<sup>1</sup> and A<sup>2</sup> are single bonds;

Het stands for a group of the formula (f);

40




45

(f)

50

and n is as defined for formula (I),  
a compound of the general formula (XII),

55




(XII)

wherein

Lip is as defined above, with the proviso that it may not be hydrogen, naphthoxy or oxo-substituted tetrahydronaphthoxy; and

n is as defined above,

is reacted with 5-nitroso-2,4,6-triaminopyrimidine of the formula (IX)



(IX)

and in the case, when Lip stands for an amine protective group, this protective group is removed from the product thus obtained, and, if desired, the compound of the general formula (I) prepared by any of the above processes a) - h) is converted to its acid addition salt.

The leaving groups L<sup>1</sup> and L<sup>2</sup> in the compounds of the general formulae (II), (VI) and (VII) may independently be e.g. halogen atoms such as chlorine, bromide or iodine; or sulfonyloxy groups, e.g. methanesulfonyloxy, benzenesulfonyloxy or p-toluene-sulfonyloxy.

An amine protective group as Lip in the compounds of the general formulae (V), (VIII), (X), (XI) or (XII) may be any group of this type being commonly used in the peptide chemistry; preferred protective groups are e.g. tert-butoxycarbonyl, formyl, benzyloxycarbonyl and the like.

The preferred embodiments of the above processes a) - h) will be discussed in detail hereinafter.

#### Process a)

The compounds of the general formula (II) are reacted with the compounds of the general formula (III) in an inert organic solvent, e.g. in a halogenated hydrocarbon such as chloroform or methylene chloride; in an alcohol such as methanol or ethanol; in an ether-like solvent such as diethyl ether or tetrahydrofuran; in acetonitrile, dimethylformamide or the like at a temperature between 0 °C and the reflux temperature of the solvent, optionally in the presence of an inorganic base, e.g. potassium carbonate or an organic base, e.g. triethylamine or pyridine. Pyridine can also be used as solvent.

The compounds of the general formula (II) used as starting substances are commercially available or can be prepared by using methods known from the literature.

It should be noted that for preparing compounds of the general formula (I), wherein

Lip means alkanoyl or alkenoyl; and

A<sup>1</sup> is a single bond,

the acyl groups mentioned above may be introduced also by using carboxylic acids of the general formula (II) wherein L<sup>1</sup> stands for hydroxy. In such cases the reaction with the compounds of the general formula (III) is preferably carried out in the presence of a condensing agent such as carbonyldiimidazole or a carbodiimide, e.g. dicyclohexylcarbodiimide or the like.

Certain compounds of the general formula (III) are known from the literature [see e.g. the published PCT patent application No. Wo 87/01706; T. H. Althuis and H. J. Hess: J. Med. Chem. **20**, 146 (1977)]; while other analogues can be prepared by using the methods illustrated by the Examples hereinbelow.

#### Process b)

The compounds of the general formula (IV) are reacted with the compounds of the general formula (III) in an inert solvent such as an alcohol, e.g. methanol or ethanol, at a temperature between room temperature and the reflux temperature of the solvent.

The starting substances of the general formula (IV) are known from the literature or can be prepared in an analogous way [E. Fourneau and M. Trefouel, Bull. Soc. Chim. France [4], **43**, 454 (1928)].

Process c)

The compounds of the general formula (V) are reacted with the compounds of the general formula (VI) under similar conditions as described for process b) above, at a temperature between 50 °C and 200 °C.

- 5 The starting substances of the general formulae (V) and (VI) are known or can be prepared by analogy of the known compounds [see e.g. P.E. Aldrich et al., J. Med. Chem. **14**, 535 (1971); B. Roth et. al., J. Am. Chem. Soc. **72**, 1914 (1950); J. Mowry, J. Am. Chem. Soc. **75**, 1909 (1953); the published German patent application No. 2,550,111 and the published PCT patent applications Nos. WO 87/01706 and WO 88/08424].

10 Process d)

The compounds of the general formula (VII) are reacted with the compounds of the general formula Lip-H in an inert organic solvent such as a polar solvent, e.g. acetonitrile or dimethylformamide; a halogenated hydrocarbon, e.g. chloroform or methylene chloride, optionally in the presence of an inorganic base, e.g. potassium carbonate or an organic base, e.g. triethylamine or pyridine, at a temperature between 0 °C and the boiling point of the solvent. Alternatively, a salt (e.g. alkali metal salt) of the compounds of the general formula Lip-H may be formed with a suitable base and reacted with the compound of the general formula (VII).

The starting substances of the general formula (VII) can conveniently be prepared by reaction of the appropriate compound of the general formula (III) with a compound of the general formula L<sup>1</sup>-A<sup>1</sup>-L<sup>2</sup>, wherein

- 20 A<sup>1</sup> is as defined for the general formula (I) in the introduction, with the proviso that it may not be a single bond; and

L<sup>1</sup> and L<sup>2</sup> stand independently for leaving groups, under conditions described for process a) above.

25 Process e)


The compounds of the general formula (VIII) are reacted with 5-nitroso-2,4,6-triaminopyrimidine of the formula (IX) under the usual conditions described in the literature for the preparation of 2,4,7-triamino-6-arylpteridines [see e.g. D. J. Brown in: "Fused Pyrimidines", pages 113-120 and 359-360 in the series "The Chemistry of Heterocyclic Compounds", Eds. E. C. Taylor and A. Weissberger, John Wiley and Sons, Interscience (1988); further the Hungarian patent specification No. 195,817] in an inert solvent, such as a substituted alcohol, e.g. 2-methoxyethanol or 2-ethoxyethanol, or dimethylformamide, N-methylpyrrolidone or the like at a temperature between room temperature and the reflux temperature of the solvent, preferably at a temperature between 100 °C and 140 °C, in the presence of a strong base, such as an alkali metal hydroxide, carbonate or alkoxide, e.g. sodium hydroxide, potassium carbonate or sodium 2-ethoxyethoxide.

- 35 When in process e) a compound of the general formula (I) containing an amine protective group as Lip is prepared, the protective group can be removed by any usual method known per se, e.g. in a separate reaction step. The method used for removing the protective group is chosen according to the nature of the protective group in question. Thus e.g. a tert-butoxycarbonyl may be removed in an aqueous or anhydrous medium by using a suitable acid, e.g. hydrochloric acid, formic acid or trifluoroacetic acid; benzyloxycarbonyl may be cleaved off e.g. by catalytic hydrogenation; whereas formyl may be removed by using e.g. a strong mineral acid, such as hydrochloric acid or a strong base such as an alkali metal hydroxide under heating. Alternatively, the compounds of the general formula (I) containing an amine protective group as Lip may be further reacted without isolation, i.e. the protective group may be removed in the same reaction mixture used for the preparation of the protected compound. In this case the unprotected final compounds of formula (I) wherein Lip is hydrogen are isolated and purified.

The starting compounds of the general formula (VIII) may be prepared e.g. by any of two methods illustrated by the following reaction scheme.

50

55



According to method A) shown in the reaction scheme, first a compound of the general formula (Va) [i.e. a compound of the general formula (V), wherein A<sup>1</sup> is a single bond], wherein

Lip and n are as defined in the introduction for the general formula (I), with the proviso that Lip may not be hydrogen, is reacted either with a compound of the general formula L<sup>1</sup>-A<sup>2</sup>-L<sup>2</sup>, wherein

A<sup>2</sup> is as defined for the general formula (I) in the introduction, with the proviso that it may not be a single bond, and

L<sup>1</sup> and L<sup>2</sup> are independently leaving groups, or with epichlorohydrine e.g. under conditions described for process a) above to obtain a compound of the general formula (XIII) or (XIV)

wherein

Lip, n and A<sup>2</sup> are as defined for the general formula (I) in the introduction, with the proviso that A<sup>2</sup> may not be a single bond; and

L<sup>2</sup> means a leaving group.

5 Subsequently the compound of the general formula (XIII) or (XIV) thus obtained is reacted with a substituted benzyl cyanide of the general formula (XV)

wherein

10 X means oxygen, sulfur or nitrogen optionally substituted by lower alkyl, in an inert organic solvent, optionally in the presence of a base to obtain the desired intermediate of the general formula (VIII).

Alternatively, according to method B) shown in the scheme, first a substituted benzyl cyanide of the general formula (XV), wherein X is as defined above, is reacted either with a compound of the general formula L<sup>1</sup>-A<sup>2</sup>-L<sup>2</sup>, wherein L<sup>1</sup>, L<sup>2</sup> and A<sup>2</sup> are as defined above, or with epichlorohydrine e.g. under conditions described for the above method A) in a manner known per se. Then the compound of general formula (XVI) or (XVII) thus obtained is reacted with a compound of the general formula (Va), wherein Lip and n are as defined above, to obtain the desired intermediate of the general formula (VIII).

The starting substances used in the two methods described above, i.e. the compounds of the general formulae (Va) and (XV) are known or can be prepared by using known methods as described hereinafter in the Examples. The compounds of the general formula L<sup>1</sup>-A<sup>2</sup>-L<sup>2</sup> are similarly known; preferred compounds of this type are e.g. 1-bromo-3-chloropropane and 2-chloroacetyl chloride.


5-Nitroso-2,4,6-triaminopyrimidine of formula (IX) used as starting substance in the present process is also known [see e.g. H. Sato et al., J. Chem. Soc. Japan, Pure Chem. Sect. 72, 866 (1951)].

#### Process f)

25

The compounds of the general formula (X) can be reacted with benzyl cyanide e.g. by using the method described in process e) and a protective group optionally present may be removed e.g. in the same way as described therein.

30 The starting compounds of the general formula (X) can be prepared e.g. in such a way that first a compound of the general formula (Va),




35

wherein

40 Lip and n are as defined for the general formula (I) in the introduction, with the proviso that Lip may not be hydrogen, is reacted with S-methylisothiuronium iodide in a manner described e.g. in the published European patent application No. 0,039,190 to obtain piperazinylamidine hydroiodide of the general formula (XVIII),

45




50

55 wherein

Lip and n are as defined for the formula (Va). Subsequently a salt of the general formula (XIX),





wherein


Lip and n are as defined for the formula (Va),  
 15 is formed from the compound of the general formula (XVIII) above by reaction with isonitrosomalonitrile using e.g. the method described by E. C. Taylor et al. [J. Am. Chem. Soc. 81, 2442 (1959)]. Finally the salt of the general formula (XIX) thus obtained is isomerized to the desired intermediate of the general formula (X) by heating it with a suitable base, such as an alkali metal hydroxide or alkali metal carbonate.

It should be noted that the last step (isomerization) of the preparation of compounds of the general formula  
 20 (X) and the subsequent reaction with benzyl cyanide to give the compounds of the general formula (I) can conveniently be carried out in the same reaction mixture without isolation of the compound of the general formula (X), e.g. in the manner described in the Hungarian patent specification No. 195,815.

#### Process g)

25 The compounds of the general formula (XI) may be reacted with benzyl cyanide under the conditions described for process e) and a protective group eventually present may similarly be removed e.g. in the way described therein.

30 The starting substances of the general formula (XI) may be prepared e.g. in such a way that a compound of the general formula (XX),



45 wherein

Lip and n are as defined for the general formula (I) in the introduction, with the proviso that Lip may not be hydrogen, is treated with nitrous acid by using the method described in the above-cited paper of H. Sato et. al., see the discussion of process e).


50 The compounds of the general formula (XX) used as starting substances can be prepared from 4-chloro-2,6-diaminopyrimidine and an appropriate compound of the general formula (Va) in a manner known per se (see the British patent specification No. 2,198,132).

#### Process h)

55

The compounds of general formula (XII) can be reacted with 5-nitroso-2,4,6-triaminopyrimidine of the formula (IX) e.g. under the conditions described for process e); and a protective group eventually present may be removed similarly to the method described therein.

The starting substances of the general formula (XII) may be prepared from ethyl cyanoacetate and the appropriate compound of the general formula (Va)



wherein

Lip and n are as defined for the compounds of the general formula (I) in the introduction, by using known methods [see e.g. T. S. Osden et al., J. Med. Chem. 10, 165 (1967)].

15 The acid addition salts of the compounds of the general formula (I) may be prepared by using any general method known per se, e.g. by reacting a base of the general formula (I) with 1-4 equivalents of the desired acid in an inert organic solvent, water or in a mixture thereof and then isolating the salt obtained by any known method (e.g. filtration, evaporation of the solvent, trituration with a solvent and/or precipitation with a non-solvent).

20 When a protective group is removed from a compound of the general formula (I) containing an amine protective group as Lip by using an acid, the corresponding acid addition salt of the compound of the general formula (I) containing hydrogen as Lip can directly be obtained.

The compounds of the general formula (I) of the present invention and their pharmaceutically acceptable acid addition salts are endowed with valuable biological activities. More particularly, these compounds inhibit 25 the peroxidation of lipids and are thereby useful for the treatment and/or prevention of diseases and conditions in which the inhibition of the lipid peroxidation is desirable.

The lipid peroxidation inhibitory activity of the compounds of the present invention and of the pharmaceutically acceptable salts thereof was demonstrated and determined by biochemical and pharmacological studies. Hereinafter, several tests and the results obtained in these tests for the compounds of the invention will be 30 described.

In these studies known lipid peroxidation inhibitors such as 3,5-di(tert-butyl)-4-hydroxytoluene ["butylated hydroxytoluene", BHT, see e.g. W. Snipes et al., Science 188, 64 (1975)],  $\alpha$ -tocopherol (vitamin E, see e.g. the paper of M.J. Kelly cited above); further 21-[4-[2,6-di(1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-16a-methyl-pregna-1,4,9(11)-triene-3,20-dione [U74006F, see e.g. J. M. Braugher et al., J. Biol. Chem. 262, 10438 (1987)], and 2-[4-[2,6-di(1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]methyl-6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-1-benzopyrane [U78517F, see e.g. E. D. Hall et al., J. Pharmacol. Exp. Ther. 258, 688 (1991)] were used as reference compounds. 35

#### Biochemical investigations

40 1. The ferrous ion dependent lipid peroxidation inhibitory activity was measured on rat brain homogenate by using the method described by J. M. Braugher et al., [J. Biol. Chem. 262, 10438 (1987)] and J. A. Buege and S. D. Aust [Methods in Enzymology 52, 302 (1978)]. The  $IC_{50}$  values (expressed in micromols) of some compounds of the invention and those of the reference compounds determined in this test are summarized 45 in Table 1 below. The  $IC_{50}$  value is defined as the concentration of a test substance which reduces by 50 % the amount of the thiobarbituric acid reactive substances (chiefly malondialdehyde) considered to be a characteristic parameter of lipid peroxidation.

Table 1

Compound(No. of Example)	IC <sub>50</sub> , $\mu$ M
<u>Reference compounds</u>	
BHT	1
$\alpha$ -tocopherol	7
U74006F	39
U78517F	0.3
<u>Compounds of the invention</u>	
1	30
3	52
9	51
12	18
20	94
22	13
23	9
26	19
27	8
30 <sup>1)</sup>	12
33	20
36	30

<sup>1)</sup>Hydrogentartrate

2. The inhibition of the ferrous ion dependent peroxidation of arachidonic acid was also measured by the method of J.M. Braugher et al. [J. Biol. Chem. 262, 10438 (1987)] and J. A. Buege and S. D. Aust [Methods in Enzymology 52, 302 (1978)]. The IC<sub>50</sub> values (expressed in micromols) of some compounds of the invention, further those of the reference compounds determined in this test are shown in Table 2.

Table 2

5	Compound(No. of Example)	IC <sub>50</sub> , $\mu$ M
	<u>Reference compounds</u>	
	BHT	>100
10	$\alpha$ -tocopherol	2
	U74006F	>100
	U78517F	> 50
15	<u>Compounds of the invention</u>	
	37 <sup>1)</sup>	17
	50 <sup>1)</sup>	15
	51 <sup>1)</sup>	28
20	52 <sup>1)</sup>	12
	53 <sup>1)</sup>	0.9
	54 <sup>1)</sup>	17
	57 <sup>2)</sup>	49
25	58 <sup>2)</sup>	38

<sup>1)</sup>Ditartrate<sup>2)</sup>Hydrochloride

30

3. Inhibition of the NADPH dependent lipid peroxidation was measured according to T. J. Player and A. A. Horton [J. Neurochem. 37, 422 (1981)] and Z. Duniec [Biochem. Pharmacol. 32, 2283 (1983)]. The IC<sub>50</sub> values (expressed in micromols) of some compounds of the invention, further those of the reference compounds determined in this test are given in Table 3.

35

40

45

50

55

Table 3


---

5      Compound (No. of Example)      IC<sub>50</sub>,  $\mu$ M

---

Reference compounds

10                      BHT                      2

$\alpha$ -tocopherol                      >100

                    U74006F                      >100

15                      U78517F                      0.7

Compounds of the invention

                    23                      13

20                      26                      59

                    27                      22

                    30<sup>1)</sup>                      16

---

25      <sup>1)</sup>Hydrogentartrate

Pharmacological investigations

30      1. The compounds of the present invention as well as the reference compounds inhibited the acute brain injury of mice described by E. D. Hall et al. [J. Neurosurg. 68, 456 (1988)]. The doses of the test compounds administered by the intravenous route and the percentage of improvement in the neurological state are summarized in Table 4.

35

40

45

50

55

Table 4

5	Compound (No. of Example)	Dose, mg/kg	Improvement, %
10	<u>Reference compounds</u>		
	$\alpha$ -tocopherol	30	97
	U74006F	30	77
	U78517F	20	31
15	<u>Compounds of the invention</u>		
	1	10	68
	12	10	46
20	27	20	82
	50 <sup>1)</sup>	20	93

<sup>1)</sup> Ditartrate

25

2. In the test described by D. A. Parks et al. [Surgery 92, 896 (1982)] the compounds of the invention inhibited the ischemia induced weight increase of a definite section in the small intestine of rats. The percentage of inhibition observed after administration of a 25 mg/kg oral dose of the compounds of the invention or of the reference compounds is shown in Table 5.

30

35

40

45

50

55

Table 5

	Compound(No. of Example)	Inhibition, %
5		
	<u>Reference compounds</u>	
	$\alpha$ -tocopherol	-
10	U74006F	59
	U78517F	20
	<u>Compounds of the invention</u>	
	1	55
15	3	31
	4	46
	6	25
20	7	34
	9	37
	10	56
	11	57
25	12	52
	15	32
	16	45
30	18 <sup>1)</sup>	31
	20	28
	23	52
	24	20
35	25	35
	26	45
	27	60

40

45

50

55

Table 5 (continued)

	Compound(No. of Example)	Inhibition, %
5	28	64
	30 <sup>2)</sup>	42
10	31	79
	33	53
	34	69
15	36	24
	37 <sup>3)</sup>	35
	39	34
	50 <sup>3)</sup>	78
20	52 <sup>3)</sup>	34
	53 <sup>3)</sup>	56
	54 <sup>3)</sup>	56
	55 <sup>3)</sup>	47
25	56 <sup>3)</sup>	44
	59 <sup>3)</sup>	30

30<sup>1)</sup>Hydrochloride  
<sup>2)</sup>Hydrogentartrate  
<sup>3)</sup>Ditartrate

### 35 Toxicity

The acute toxicity of certain compounds of the invention was determined in rats and generally it was found to be favourably low. Thus e.g. a 1000 mg/kg oral dose of the compounds of Examples 1, 10, 27, 28, 34 and 50 did not provoke death of any of the treated animals (i.e. LD<sub>50</sub> > 1000 mg/kg), similarly to the toxicity measured for the reference compound U74006F mentioned above.

The above data demonstrate that several compounds of the general formula (I) of the present invention inhibit the peroxidation of lipids in vitro. Thereby these compounds are capable to suppress various pathological processes accompanied by an increased rate of lipid peroxidation in the living organism as it was proven by the results of the above in vivo investigations. In addition, this favourable activity is accompanied by low toxicity.

For therapeutic purposes the compounds of the present invention and their pharmaceutically acceptable salts may be used alone or preferably in the form of pharmaceutical compositions. Such compositions contain as active ingredient a compound of the general formula (I) or its pharmaceutically acceptable acid addition salt in an amount which is sufficient to produce the desired effect, in admixture with known carriers, excipients, diluents and/or other additives commonly used in the pharmaceutical practice.

The present invention also relates to a method for inhibiting the peroxidation of lipids and for treating diseases and conditions wherein the inhibition of lipid peroxidation is desirable. This method comprises of administering a therapeutically effective amount of an active ingredient of the formula (I) or of its pharmaceutically acceptable salt to a patient in need of such treatment.

Although the therapeutically effective dose of the compounds of the present invention may vary and depend upon the condition and age of each individual patient to be treated and will ultimately be determined by the attending physician, generally a daily oral dose of these compounds between about 0.1 mg and about 100 mg per kg body weight may be used for the prevention and/or treatment of diseases wherein inhibition of lipid



peroxidation is desirable.

The present invention is further illustrated in detail by the following non-limiting examples.

#### Example 1

5

##### 1-(10-Undecenoyl)-4-[2,6-di(1-pyrrolidinyl)-4-pyrimidinyl]piperazine

To a solution of 1-[2,6-di(1-pyrrolidinyl)-4-pyrimidinyl]piperazine (2.25 g, 7.4 mmol) in anhydrous pyridine (45 ml) 10-undecenoyl chloride (1.85 ml, 1.75 g, 8.6 mmol) was added dropwise under stirring at 0-5 °C. The reaction mixture was stirred at the same temperature for one hour and then poured into 450 ml of water. After 15 minutes of stirring the yellow powderlike precipitate was collected, washed with water and dried. Recrystallization of this crude product from acetonitrile afforded 2.86 g of the title compound, yield : 82.0 %, mp. 93-96 °C.

The starting 1-[2,6-di(1-pyrrolidinyl)-4-pyrimidinyl]piperazine can be prepared e.g. as described in the literature (published PCT application WO 87/01706).

The 1-[2,6-di(1-pyrrolidinyl)-4-pyrimidinyl]homopiperazine was prepared in a similar manner, yield : 68.4 %, mp. 106-110 °C.

#### Example 2

20

##### 1-(n-Octadecanoyl)-4-[2,6-di(1-pyrrolidinyl)-4-pyrimidinyl]piperazine

By following the procedure of Example 1, with the difference that n-octadecanoyl chloride was used instead of 10-undecenoyl chloride, the title compound was obtained in a yield of 50.0 %, mp. 102-104 °C.

25

#### Example 3

##### 1-(10-Undecenoyl)-4-(2,6-diamino-4-pyrimidinyl)-piperazine

A mixture of 1-(2,6-diamino-4-pyrimidinyl) piperazine-bis- trifluoroacetate (1.26 g, 3.0 mmol) and anhydrous potassium carbonate (1.38 g, 10.0 mmol) in acetonitrile (120 ml) was stirred under reflux for 30 minutes. Then 10-undecenoyl chloride (0.74 ml, 0.70 g, 3.4 mmol) was added dropwise and stirring under reflux was continued for one hour. After cooling the solvent was evaporated under reduced pressure and the residue was partitioned between methylene chloride (100 ml) and water (100 ml). The aqueous layer was separated and extracted twice with methylene chloride (40 ml each). The combined organic extracts were washed with water twice (until neutral), dried over MgSO<sub>4</sub> and concentrated under reduced pressure. The obtained crude product was triturated with isopropyl ether. In this manner 1.5 g of the title compound was obtained as a crystalline substance, yield : 69.4 %, mp. 100-104 °C.

The starting 1-(2,6-diamino-4-pyrimidinyl)piperazine-bistrifluoroacetate was prepared by following step c) of Example 60 and deprotecting thus 1-(tert-butoxycarbonyl)-4-(2,6-diamino-4-pyrimidinyl)piperazine which in turn was prepared as described in step a) of Example 59. Mp. of the obtained bis-trifluoroacetate : 192-198 °C, yield : 98.7 %.

The analogous 1-(2,6-diamino-4-pyrimidinyl)homopiperazine was prepared by reaction of 2,6-diamino-4-chloropyrimidine with unprotected homopiperazine (5 mol equivalents) in ethanol in a sealed tube, following the procedure of Example 19. Yield of the obtained base : 91.3 %, mp. 62-72 °C.

#### Examples 4-8

By using appropriate starting compounds, the procedure of Example 3 was followed to prepare the compounds of formula (I) listed in Table 6, wherein each of A<sup>1</sup> and A<sup>2</sup> stand for a single bond, Lip and n are as given in the Table and Het represents a group of the general formula (a) wherein R<sup>1</sup> is as given in the Table.

55

Table 6

No. of Example	Lip	n	R <sup>1</sup>	Mp., °C	Yield, %
4	octadecyl	1	NH <sub>2</sub>	121-123	54.5
5	octadecyl	1	1-pyrrolidinyl	75-77	68.2 <sup>1)</sup>
6	octadecanoyl	2	1-pyrrolidinyl	63-66	95.0 <sup>1)</sup>
7	octadecanoyl	1	NH <sub>2</sub>	110-114	88.4
8	9-octadecenoyl	1	1-pyrrolidinyl	75-82	45.1 <sup>1)</sup>

<sup>1)</sup>The base form of the starting piperazine derivative was used, in the presence of 2 mol equivalents of K<sub>2</sub>CO<sub>3</sub>.

#### Example 9

#### 1-Trityl-4-(2,6-diamino-4-pyrimidinyl) piperazine

A mixture of 1-(2,6-diamino-4-pyrimidinyl)piperazine-bistrifluoroacetate (2.1 g, 5.0 mmol), potassium carbonate (1.0 g, 7.5 mmol) and trityl chloride (1.36 g, 5.0 mmol) in acetonitrile (50 ml) was stirred vigorously at room temperature. After 3 hours the solvent was evaporated under reduced pressure and the solid residue was stirred with 100 ml of water at room temperature for one hour. The yellow powderlike substance was collected, washed with water and dried. This crude product was purified by column chromatography over silica gel eluting with a 9:1 mixture of methylene chloride and methanol to give 0.88 g of the title compound, yield : 40.4 %, mp.152-160 °C.

#### Example 10-14

By using appropriate starting compounds, the procedure of Example 9 was followed to prepare the compounds of formula (I) listed in Table 7, wherein each of A<sup>1</sup> and A<sup>2</sup> stand for a single bond,

Lip and n are as given in the Table and

Het represents a group of the general formula (a) wherein

R<sup>1</sup> is as given in the Table.

Table 7

No. of Example	Lip	n	R <sup>1</sup>	Mp., °C	Yield, %
10	trityl	1	1-pyrrolidinyl	246-250	33.5
11	trityl	2	1-pyrrolidinyl	215-218	59.1
12	o-chlorotrityl	1	NH <sub>2</sub>	160-170	62.0
13	o-chlorotrityl	1	1-pyrrolidinyl	242-250	54.2
14	o-chlorotrityl	2	1-pyrrolidinyl	151-152	46.6

Examples 15-17

By using appropriate starting compounds, the procedure of Example 9 was followed to prepare the compounds of formula (I) listed in Table 8, wherein

5 each of A<sup>1</sup> and A<sup>2</sup> stand for a single bond and  
Lip, Het and n are as given in the Table.

10 Table 8

No. of Example	Lip	n	Het	Mp., °C	Yield, %
15	o-chlorotrityl	1	4,7-diamino-6-phenyl-2-pteridinyl	250-252	56.8 <sup>1)</sup>
20	o-chlorotrityl	1	2,4,7-triamino-6-pteridinyl-carbonyl	>260 (dec.)	51.6 <sup>2)</sup>
25	o-chlorotrityl	1	4-amino-6,7-dimethoxy-2-quinazolinyl	164-168	73.7

30 <sup>1)</sup> Starting with the compound of Example 58

<sup>2)</sup> Starting with the compound of Example 60

35 Example 18

1-(1-Adamantyl)-4-(4-chloro-3-oxo-2,3-dihydro-5-pyridazinyl)-piperazine

40 A mixture of 1-(1-adamantyl)piperazine (2.2 g, 10 mmol), triethylamine (1.36 ml, 10 mmol) and 4,5-dichloro-3-oxo-2,3-dihydro-pyridazine (1.65 g, 10 mmol) in ethanol (25 ml) was heated under reflux for 5 hours. After cooling the precipitated solids were collected, washed with ethanol and dried to afford 2.57 g of the title compound, yield : 73.6 %, mp. 292-294 °C.

45 The above product was dissolved in a hot mixture of ethanol (25 ml), water (6 ml) and conc. HCl (2 ml), and the solution was treated with decolorizing carbon. After filtration, upon cooling the hydrochloride of the title compound separated as colorless crystals, yield : 2.0 g, mp. 306-308 °C.

Example 19

1-(1-Adamantyl)-4-(2,6-diamino-4-pyrimidinyl)-piperazine

50 A mixture of 2,6-diamino-4-chloropyrimidine (0.43 g, 3.0 mmol) and 1-(1-adamantyl)-piperazine (0.66 g, 3.0 mmol) in ethanol (30 ml) was heated in a sealed tube at 170 °C for 3 hours. After cooling the solvent was removed, the solid residue was dissolved in water (45 ml) and acidified to pH=3 with conc. HCl. The obtained mixture was heated to 50 °C, the insolubles were filtered off, and the clear solution was rendered alkaline with 10 N NaOH under stirring and cooling. The precipitated crystals were collected, washed with water until neutral and dried. In this manner 0.79 g of the title compound was obtained in the form of its monohydrate, yield :  
55 76.6%, mp. 265-268 °C.

Example 201-[2-Hydroxy-3-(1-naphthoxy)-propyl]-4-(2,6-diamino-4-pyrimidinyl)piperazine

A mixture of 1-(2,6-diamino-4-pyrimidinyl)piperazine-bis- trifluoroacetate (0.85 g, 2.0 mmol) and potassium carbonate (0.69 g, 5.0 mmol) in ethanol (60 ml) was stirred under reflux for 30 minutes. The mixture was filtered hot and to the filtrate a solution of 1,2-epoxy-3-(1-naphthoxy)-propane (0.6 g, 3.0 mmol) in ethanol (10 ml) was added. The mixture was heated under reflux for 3 hours, the solvent was evaporated and the residue was partitioned between ethyl acetate (80 ml) and water (80 ml). The aqueous layer was separated and extracted with ethyl acetate (40 ml). The combined organic extracts were washed once with brine, dried over  $\text{MgSO}_4$  and concentrated. The residue was chromatographed on a silica gel column eluting with a 75:20:5 mixture of ethyl acetate, methanol and conc.  $\text{NH}_4\text{OH}$ . In this manner 0.58 g of the title compound was obtained as a foam, yield : 74.3 %. Mp. after trituration with isopropyl ether : 122-124 °C.

The starting epoxide of formula (IV) wherein Lip stands for 1-naphthoxy can be prepared by a known method, see E. Fourneau, M. Trefouel, Bull. Soc. chim. France [4], 43, 454 (1928).

Examples 21-30

By using appropriate starting compounds, the procedure of Example 20 was followed to prepare the compounds of formula (I) listed in Table 9, wherein

A<sup>1</sup> stands for 2-hydroxy-1,3-propylene,

A<sup>2</sup> stands for a single bond,

Lip and n are as given in the Table and

Het represents a group of the general formula (a) wherein

R<sup>1</sup> is as given in the Table.

Table 9

No. of Example	Lip	n	R <sup>1</sup>	Mp., °C	Yield, %
21	1-naphthyloxy	2	NH <sub>2</sub>	120-125	39.2
22	1-naphthyloxy	1	1-pyrrolidinyl	132-138	63.4
23	1-naphthyloxy	2	1-pyrrolidinyl	56-58	61.2
24	2-naphthyloxy	1	NH <sub>2</sub>	224-228	67.8
25	2-naphthyloxy	2	NH <sub>2</sub>	57-63	39.3
26	2-naphthyloxy	1	1-pyrrolidinyl	145-147	48.7
27	2-naphthyloxy	2	1-pyrrolidinyl	102-106	72.9
28	1-oxo-1,2,3,4-tetrahydro-6-naphthyloxy	1	NH <sub>2</sub>	194-197	28.5
29	1-oxo-1,2,3,4-tetrahydro-6-naphthyloxy	1	1-pyrrolidinyl	146-150	64.1
30	1-oxo-1,2,3,4-tetrahydro-6-naphthyloxy	2	1-pyrrolidinyl	182-186 <sup>1)</sup>	62.5

<sup>1)</sup>Hydrogentartrate

1,2-Epoxy-2-(2-naphthyloxy)-propane (mp. 51-56 °C, yield : 52.7 %) and 1,2-epoxy-3-(1-oxo-1,2,3,4-tetrahydro-6-naphthyloxy)propane (oil, yield : 87.9 %) used as starting compounds in Examples 24-30 were prepared by the method of E. Fourneau and M.Trefouel cited above.

Example 311-[2-(1-Naphthyloxy)acetyl]-4-(2,6-diamino-4-pyrimidinyl)-piperazine

A suspension of 1-(2,6-diamino-4-pyrimidinyl)piperazine-bis- trifluoroacetate (1.1 g, 2.5 mmol) and potassium carbonate (1.38 g, 10 mmol) in acetonitrile (100 ml) was stirred vigorously under reflux for 30 minutes. Then a solution of 2-(1-naphthyloxy)acetyl chloride (0.65 g, 3.0 mmol) in acetonitrile (5 ml) was added dropwise and the mixture was heated under reflux for one hour. Thereafter the insolubles were filtered off while hot and the filtrate was concentrated. The residue was stirred with 100 ml of water for one hour, the precipitate formed was collected, washed with water until neutral and dried to give 0.90 g of the title compound, yield : 59.2 %, mp. 205-210 °C.

Example 321-[2-(2-Naphthyloxy)acetyl]-4-[2,6-di(1-pyrrolidinyl)-4-pyrimidinyl]homopiperazine

To a solution of 2-(2-naphthyloxy)acetic acid (1.1 g, 5.0 mmol) in anhydrous tetrahydrofuran (25 ml) carbonyl-diimidazole (0.80 g, 5.0 mmol) was added in portions, under stirring at room temperature. After 15 minutes a solution of 1-[2,6-di(1-pyrrolidinyl)-4-pyrimidinyl]homopiperazine (1.58 g, 5.0 mmol) in anhydrous tetrahydrofuran (15 ml) was added dropwise. The mixture was stirred at room temperature for 8 hours and the sol-

vent was distilled off under reduced pressure. The residue was dissolved in methylene chloride, the solution was washed three times with water, dried over  $\text{MgSO}_4$  and concentrated. The obtained crude product was chromatographed over a silica gel column eluting with a 1:2 mixture of benzene and ethyl acetate to afford 0.7 g of the title compound, yield: 28 %, mp. 103-110 °C.

5

### Example 33

#### 1-[2-(1-Naphthyloxy)acetyl]-4-[2,6-di(1-pyrrolidinyl)-4-pyrimidinyl]piperazine

Metallic sodium (0.069 g, 3 mg-atom) was dissolved in anhydrous ethanol (4 ml) and the obtained solution was added to a mixture of 1-naphthol (0.36 g, 2.2 mmol) and 1-(2-chloroacetyl)-4-[2,6-di(1-pyrrolidinyl)-4-pyrimidinyl]piperazine ((0.9 g, 2.4 mmol) in ethanol (30 ml). The reaction mixture was heated under reflux for 4 hours, cooled to room temperature and the insolubles were filtered off. The filtrate was concentrated to dryness and the residue was chromatographed over a silica gel column eluting with a 1:2 mixture of benzene and ethyl acetate. By triturating the obtained product with isopropyl ether 0.75 g of the title compound was obtained, yield : 72.0 %, mp. 156-160 °C.

The starting 1-(2-chloroacetyl)-4-[2,6-di(1-pyrrolidinyl)-4-pyrimidinyl]piperazine was prepared as follows : 1-[2,6-di(1-pyrrolidinyl)-4-pyrimidinyl]piperazine (1.65 g, 5.4 mmol) was dissolved in anhydrous chloroform (30 ml), the solution was cooled to 0-5 °C and 2-chloroacetyl chloride (0.50 ml, 0.79 g, 7.0 mmol) in anhydrous chloroform (5 ml) was added dropwise under stirring. The mixture was stirred for one-hour, concentrated and the residue was dissolved in 100 ml of water. The aqueous solution was made alkaline with conc.  $\text{NH}_4\text{OH}$  and stirred for one hour. During this period the separated oil solidified. The solids were collected, washed with ice-cold water until neutral and dried. In this manner 2.0 g of the desired chloroacetyl compound was obtained, yield : 97.0 %, mp. 153-156 °C.

1-(2-Chloroacetyl)-4-[2,6-di(1-pyrrolidinyl)-4-pyrimidinyl]-homopiperazine was prepared in a similar manner and was obtained as a tan viscous oil, yield : 98.2 %.

### Examples 34-36

By using appropriate starting compounds, the procedure of Example 31 or 32 was followed to prepare the compounds of formula (I) listed in Table 10, wherein

A<sup>1</sup> stands for  $\text{CH}_2\text{CO}$ ,

A<sup>2</sup> stands for a single bond,

Lip and n are as given in the Table and

Het represents a group of the general formula (a) wherein

R<sup>1</sup> is as given in the Table.

Table 10

No. of Example	Lip	n	R <sup>1</sup>	Method (Example)	Mp., °C	Yield, %
34	2-naphthyloxy	1	$\text{NH}_2$	31	100-103	52.9
35	2-naphthyloxy	1	1-pyrrolidinyl	31	153-156	48.0
36	1-naphthyloxy	2	1-pyrrolidinyl	32	135-140	51.3

45

### Example 37

#### 6-[4-[3-[4-(1-Adamantyl)-1-piperazinyl]-2-hydroxypropoxy]phenyl]-2,4,7-triaminopteridine

A mixture of 4-[3-[4-(1-adamantyl)-1-piperazinyl]-2-hydroxy-propoxy]benzylcyanide (3.44 g, 8.4 mmol), 5-nitroso-2,4,6-triamino-pyrimidine (1.08 g, 7.0 mmol) and 0.2 N sodium-(2-ethoxyethoxide) in 2-ethoxyethanol (35 ml) was stirred at 120 °C for 30 minutes. After cooling to about 90 °C 100 ml of water was added and the mixture was cooled to room temperature followed by stirring in an ice-water bath for 30 minutes. The precipitate was collected, washed with water and acetonitrile to give the title compound (3.23 g) as a yellow powder, mp. 287-289 °C (dec.), yield : 84.6 %.

0.27 g (0.5 mmol) of the above product was dissolved in a hot solution of L(+)-tartaric acid (0.23 g, 1.5 mmol) in water (1 ml), and the obtained solution was allowed to cool. The precipitated crystals were collected,

washed with acetonitrile and dried to give the ditartrate pentahydrate of the title compound, mp. 165-175 °C, yield of the salt formation : 38.3 %.

The starting 4-[3-[4-(1-adamantyl)-1-piperazinyl]propoxy]benzyl-cyanide was prepared as follows :  
A solution of 1-(1-adamantyl)piperazine (4.4 g, 20 mmol) 4-(2,3-epoxypropoxy)benzylcyanide (2.9 g, 15.4 mmol) in methanol (45 ml) was stirred at room temperature for 4 hours. Then the solvent was removed under reduced pressure and the residue was dissolved in ethyl acetate. The solution was washed with water, dried over MgSO<sub>4</sub> and concentrated under reduced pressure. Trituration of the residue afforded 3.67 g of the desired substituted benzylcyanide as pale yellow crystals, yield : 45.8 %, mp. 136-138 °C.

#### Example 38

##### 6-[4-[2-Hydroxy-3-[4-(tert-butoxycarbonyl)-1-piperazinyl]propoxy]phenyl]-2,4,7-triaminopteridine

Sodium metall (0.22 g, 9.6 mg-atom) was dissolved in 2-ethoxyethanol (60 ml) at 40-50 °C, the solution was cooled to room temperature and 5-nitroso-2,4,6-triamino-pyrimidine (1.46 g, 9.5 mmol) was added, followed by 4-[2-hydroxy-3-[4-(tert-butoxycarbonyl)-1-piperazinyl]propoxy]benzylcyanide (3.92 g, 10.4 mmol) prepared as described in Example 45. The mixture was stirred under reflux in an atmosphere of nitrogen for one hour and the obtained dark brown solution was cooled to room temperature. After dilution with 200 ml of ethyl acetate the precipitate was collected, washed with ethyl acetate and dried to yield a yellow powder, mp. 244-246 °C (dec.). The filtrate was concentrated and the residue was dissolved in 30 ml of methanol. After treatment with decolorizing carbon the solution was concentrated to a volume of 10 ml and the separated crystals were collected. Total yield of the two generations : 84.8 %.

#### Examples 39-44

By using appropriate starting compounds, the procedure of Example 38 was followed to prepare the compounds of formula (I) listed in Table 11, wherein  
Lip is o-chlorotriyl (o-Cl-Tr) or tert-butoxycarbonyl (Boc),  
A<sup>1</sup> stands for a single bond,  
n and A<sup>2</sup> are as given in the Table and  
Het represents a group of the general formula (g) wherein  
X is as given in the Table.

Table 11

No. of Example	Lip	n	A <sup>2</sup>	X	Mp., °C	Yield, %
39	o-Cl-Tr	1	CH <sub>2</sub> CH(OH)CH <sub>2</sub>	O	220-228	62.5 <sup>1)</sup>
40	Boc	2	CH <sub>2</sub> CH(OH)CH <sub>2</sub>	O	238-240	84.2
41	Boc	1	CH <sub>2</sub> CH(OH)CH <sub>2</sub>	NH	240-241	45.7
42	Boc	1	CH <sub>2</sub> CH(OH)CH <sub>2</sub>	N(CH <sub>3</sub> )	233-235	62.1
43	Boc	1	CH <sub>2</sub> CH(OH)CH <sub>2</sub>	S	250-251	74.7 <sup>1)</sup>
44	Boc	1	CH <sub>2</sub> CO	NH	275-280	68.3 <sup>2)</sup>

<sup>1)</sup> By using 4 equivalents of NaOH as base instead of sodium-(2-ethoxy-ethoxide)

<sup>2)</sup> At 100 °C

The compounds of formula (VIII) used as starting materials in Examples 38-44 were prepared as described in Examples 45-49 below.

Example 454-[2-Hydroxy-3-[4-(tert-butoxycarbonyl)-1-piperazinyl]propoxy]benzylcyanide

A solution of 4-(2,3-epoxypropoxy)benzylcyanide (2.84 g, 15 mmol) and 1-(tert-butoxycarbonyl)piperazine (4.2 g, 22.5 mmol) in methanol (35 ml) was stirred at room temperature for 3 hours and the solvent was removed. The residue was dissolved in 200 ml of ethyl acetate, washed with water, dried over  $\text{MgSO}_4$  and concentrated. The obtained crude product was chromatographed on a silica gel column eluting with ethyl acetate. The obtained sticky material was triturated with hexane to give 3.95 g of the title compound, yield : 70.2 %, mp. 98-100 °C.

Similarly was prepared the 4-[2-hydroxy-3-[4-(tert-butoxycarbonyl)-1-homopiperazinyl]propoxy]benzylcyanide, it was obtained in a yield of 69.9 % as an oil [starting with 1-(tert-butoxycarbonyl)homopiperazine which was in turn obtained in a yield of 38.8 % as an oil by following the procedure described for the analogous piperazine derivative in the published German patent application 2,550,111].

4-[2-Hydroxy-3-[4-(o-chlorotriptyl)-1-piperazinyl]propoxy]benzylcyanide was also prepared in a similar manner, yield : 63.8 %, mp. 103-106 °C. [The starting substance for the preparation of this latter compound, i.e. 1-(o-chlorotriptyl)-piperazine was prepared from 1-formylpiperazine, by first alkylating with 1 mol equivalent of triptyl chloride in acetonitrile in the presence of 1 mol equivalent of potassium carbonate (3 hours at room temperature) and the obtained 1-formyl-4-(o-chlorotriptyl)-piperazine (mp. 245-247 °C, yield : 89.5 %) was de-formylated by refluxing with an equal weight of NaOH in butanol for 90 minutes, yield : 82.0 %, mp. 178-180 °C.]

Example 464-[2-Hydroxy-3-[4-(tert-butoxycarbonyl)-1-piperazinyl]propyl-amino]benzylcyanide

## Step a)

4-(2,3-Epoxypropyl-amino)benzylcyanide

A mixture of 4-aminobenzylcyanide (10 g, 75.7 mmol), epichlorohydrine (7.9 ml, 9.25 g, 100 mmol), ethanol (15 ml) and water (10 ml) was heated under reflux for 2 hours. After cooling the reaction mixture was poured into 100 ml of water and extracted with ether (3 x 50 ml). The organic extracts were combined and stirred with 50 ml of 10 N NaOH at room temperature for 3 hours. The organic layer was separated, washed with water until neutral, dried over  $\text{MgSO}_4$  and concentrated. The residue was chromatographed over a silica gel column eluting with a 3:1 mixture of benzene and ethyl acetate to afford 7.24 g of the title compound as an oil, yield : 51.0 %.

## Step b)

4-[2-Hydroxy-3-[4-(tert-butoxycarbonyl)-1-piperazinyl]propyl-amino]benzylcyanide

A solution of the epoxide obtained as described in step a) above (4.96 g, 26.4 mmol) and 1-(tert-butoxycarbonyl)piperazine (6.4 g, 34.4 mmol) in methanol (30 ml) was heated under reflux for 2 hours, and the product was isolated as described in Example 45.

The obtained crude product was chromatographed over a silica gel column eluting with a 9:1 mixture of ethyl acetate and methanol to give the title compound (3.68 g), mp. 86-87 °C, yield : 37.2 %.

Example 474-[N-Methyl-N-[2-hydroxy-3-[4-(tert-butoxycarbonyl)-1-piperazinyl]propyl]amino]benzylcyanide

## Step a)

4-[N-Methyl-N-(2,3-epoxypropyl)amino]benzylcyanide

A mixture of 4-methylaminobenzylcyanide (3.05 g, 20.9 mmol), epichlorohydrine (2.4 ml, 2.87 g, 31 mmol), ethanol (25 ml) and water (20 ml) was heated under reflux for 3 hours. After cooling the mixture was diluted with ethanol (10 ml) followed by addition of aqueous 10 N NaOH (6 ml). The obtained clear solution was stirred at room temperature for one hour and the ethanol was distilled off. The residue was diluted with 100 ml of water and extracted with ether (3 x 50 ml). The organic extracts were washed with brine until neutral, dried over  $\text{MgSO}_4$  and concentrated. The residue was chromatographed over a silica gel column eluting with a 3:1 mixture



of benzene and ethyl acetate to give 2.21 g of the oily title compound, yield : 52.2 %.

Step b)

5 4-[N-Methyl-N-[2-hydroxy-3-[4-(tert-butoxycarbonyl)-1-piperazinyl]propyl]amino]benzylcyanide

The epoxide prepared as described in step a) above (2.21 g, 10.9 mmol) was allowed to react with 1-(tert-butoxycarbonyl)-piperazine (3.05 g, 16.4 mmol) by following the procedure of step b) of Example 46 and the product was isolated as described therein. In this manner 4.02 g of the title compound was obtained as an oil, yield : 94.8 %.

10

Example 48

4-[2-Hydroxy-3-[4-(tert-butoxycarbonyl)-1-piperazinyl]propyl-thio]benzylcyanide

15 Step a)

4-(N,N-Dimethylthiocarbamoyloxy)benzylcyanide

Metallic sodium (1.15 g, 50 mg-atom) was dissolved in methanol (100 ml) and 4-hydroxybenzylcyanide (6.7 g, 50 mmol) was added.

20

The obtained solution was concentrated and acetonitrile (2 x 10 ml) was evaporated from the residue. The obtained salt was dissolved in anhydrous dimethylformamide (200 ml) and about 25 ml of the solvent was removed under reduced pressure. To the obtained solution N,N-dimethylthiocarbamoyl chloride (9.9 g, 80 mmol) was added and the reaction mixture was stirred at 80-85 °C for 2 hours. Thereafter additional N,N-dimethylthiocarbamoyl chloride (2.5 g, 20 mmol) was added and stirring at 80 °C was continued for further one hour. After cooling the mixture was poured into aqueous 1 % KOH (500 ml) and extracted with ether (3 x 200 ml). The organic extracts were washed with water until neutral, dried over MgSO<sub>4</sub> and concentrated. The solid residue was triturated with water and after drying also with isopropyl ether to give the title compound (5.42 g), mp. 120-124 °C, yield : 52.7 %.

25

30 Step b)

4-(N,N-Dimethylcarbamoylthio)benzylcyanide

To Dowtherm A (75 ml) preheated to 250 °C, under nitrogen the compound prepared as described in step a) above (5.05 g, 22.9 mmol) was added and the mixture was stirred at the same temperature for one hour. After cooling the reaction mixture was diluted with 200 ml of benzene, treated with decolorizing carbon and the solvents were distilled off under reduced pressure. The residue was chromatographed on a silica gel column eluting with a 3:1 mixture of benzene and ethyl acetate to afford the title compound (3.08 g) as yellow crystals, yield : 60.1 %, mp. 97-99 °C.

35

40 Step c)

1-(2,3-Epoxypropyl)-4-(tert-butoxycarbonyl)piperazine

A solution of 1-(tert-butoxycarbonyl)piperazine (18.6 g, 100 mmol) and epichlorohydrine (10.2 ml, 12.0 g, 130 mmol) in methanol (50 ml) was stirred at room temperature for 24 hours and the solvent was evaporated.

45

The residue was dissolved in 200 ml of ether and the solution was stirred with 10 N aqueous NaOH (100 ml) at room temperature for 2 hours. Then the organic layer was separated, washed with brine until neutral, dried over MgSO<sub>4</sub> and concentrated to afford the title compound (21.8 g) as a pale yellowish viscous oil, yield : 90.1 %.

50 Step d)

4-[2-Hydroxy-3-[4-(tert-butoxycarbonyl)-1-piperazinyl]propyl-thio]benzylcyanide

A mixture of the product of step b) above (3.08 g, 14 mmol), the epoxide prepared as described in step c) above (3.4 g, 14 mmol), ethanol (70 ml) and 2 N aqueous NaOH (7 ml) was heated under reflux in an atmosphere of nitrogen for 2 hours. After cooling the mixture was poured into 300 ml of water and extracted with ethyl acetate (2 x 150 ml). The organic layer was washed with brine until neutral, dried over MgSO<sub>4</sub> and concentrated. The residue was chromatographed on a silica gel column eluting with ethyl acetate to give 1.69 g of the title compound as a colorless solid, yield : 30.8 %. Mp. after trituration with hexane : 69-70 °C.

55

Example 494-[2-[4-(Tert-butoxycarbonyl)-1-piperazinyl]acetyl]amino]benzylcyanide

## 5    Step a)

4-(2-Chloroacetyl]amino]benzylcyanide

2-Chloroacetyl chloride (3.3 ml, 5.0 g, 44 mmol) was added dropwise at 10-15 °C to a solution of 4-aminobenzylcyanide (5.3 g, 40 mmol) in dimethyl acetamide (20 ml) and the mixture was stirred at room temperature for one hour. After pouring into water the precipitate was collected, washed with water and dried over  $P_2O_5$  under reduced pressure to give the title compound (7.33 g) as nearly colorless crystals, yield : 87.8 %, mp. 124-125 °C.

## Step b)

15

4-[2-[4-(Tert-butoxycarbonyl)-1-piperazinyl]acetyl]amino]benzyl-cyanide

A mixture of the product obtained according to step a) above (2.1 g, 10 mmol), 1-(tert-butoxycarbonyl)piperazine (2.4 g, 13 mmol) and potassium carbonate (1.8 g, 13 mmol) in acetonitrile (50 ml) was stirred under reflux for 2 hours. After cooling the mixture was poured into water. The precipitate was collected, washed with water and dried under reduced pressure over  $P_2O_5$  to afford 3.48 g of the title compound as nearly colorless crystals, yield : 97.2 %, mp. 137-138 °C.

Example 5025    6-[4-[2-Hydroxy-3-(1-piperazinyl)propoxy]phenyl]-2,4,7-triamino-pteridineMethod A)

A mixture of the protected compound obtained according to Example 38 (5.5 g, 10.8 mmol) and 10 % aqueous HCl (140 ml) was stirred at room temperature for 20 hours. The yellow suspension was diluted with 350 ml of water and heated to about 40 °C. The obtained solution was filtered and made alkaline with 5 N aqueous NaOH. The formed precipitate was collected, washed with water until neutral and dried to give the title compound (4.4 g) as pale yellow crystals, yield : 100 %, mp. 245-255 °C.

3.91 g (9.5 mmol) of the above product was added to a solution of L(+)-tartaric acid (3.54 g, 23.6 mmol) in water (60 ml) and the solids were dissolved by heating to reflux. The hot solution was treated with decolorizing carbon, filtered and allowed to cool. The separated crystals were collected, washed with water and acetonitrile and dried to give the ditartrate-trihydrate of the title compound, mp. 185-190 °C, yield of the salt formation: 66.9 %.

40    Method B)

A suspension of the protected compound obtained according to Example 38 (1.5 g, 3 mmol) in a 1.5 N solution of HCl in ethyl acetate (20 ml) was stirred for 5 hours at room temperature. The solids (HCl salt of the title product) were then collected and after drying dissolved in water. The solution was made alkaline with aqueous 5 N NaOH and the precipitated base was filtered off to give the title compound which was identical with the product obtained according to Method A)-above, yield : 37.0 %.

Method C)

50    A mixture of the protected compound obtained according to Example 38 (0.26 g, 0.5 mmol) and L(+)-tartaric acid (0.23 g, 1.5 mmol) in water (2.5 ml) was heated under reflux for one hour and allowed to cool to room temperature. The separated precipitate was collected to give the ditartrate-trihydrate of the title compound which was identical with the salt obtained according to Method A) above, yield : 65.8 %, mp. 169-175 °C.

55    Examples 51-55

By using the appropriate starting compounds prepared according to Examples 40-44, the procedure of Example 50 was followed to prepare the compounds of formula (I) listed in Table 12, wherein

Lip is hydrogen,  
 A<sup>1</sup> stands for a single bond,  
 n and A<sup>2</sup> are as given in the Table and  
 Het represents a group of the general formula (g) wherein  
 X is as given in the Table.

Table 12

No. of Example	n	A <sup>2</sup>	X	Method (Example)	Mp., °C <sup>1)</sup>	Yield, %
51	2	CH <sub>2</sub> CH(OH)CH <sub>2</sub>	O	50/B	163-168	48.6 <sup>2)</sup>
52	1	CH <sub>2</sub> CH(OH)CH <sub>2</sub>	NH	50/A	205-210 <sup>3)</sup>	55.9
53	1	CH <sub>2</sub> CH(OH)CH <sub>2</sub>	N(CH <sub>3</sub> )	50/B	175-180 <sup>4)</sup>	68.1
54	1	CH <sub>2</sub> CH(OH)CH <sub>2</sub>	S	50/B	250-253 <sup>3)</sup>	61.2
55	1	CH <sub>2</sub> CO	NH	50/B	90-95 <sup>5)</sup>	45.1

<sup>1)</sup>Ditartrate

<sup>2)</sup>By using 97 % HCOOH instead of HCl

<sup>3)</sup>Dihydrate ; <sup>4)</sup>Pentahydrate ; <sup>5)</sup>Heptahydrate

#### Example 56

##### 6-[4-[3-(1-Piperaziny)propylamino]phenyl]-2,4,7-triamino-pteridine

A mixture of 4-[3-(4-formyl-1-piperaziny)propylamino]benzyl- cyanide (1.15 g, 4.0 mmol), 5-nitroso-2,4,6-triamino-pyrimidine (0.56 g, 3.6 mmol) and 0.2 N sodium-(2-ethoxy-ethoxide) in 2-ethoxyethanol (18 ml) was stirred under reflux for 3 hours, then NaOH (0.14 g, 3.5 mmol) was added and stirring under reflux was continued for further 2.5 hours. After cooling the mixture was diluted with 100 ml of ether. The separated precipitate was collected, washed with ether, then with water and dried to afford the title compound (0.92 g) as a yellow powder, yield: 64.8 %.

The above product was dissolved in a hot solution of L-(+)-tartaric acid (0.75 g, 5 mmol) in water (6 ml) and after cooling the mixture was diluted with methanol (6 ml). The separated crystals were collected, washed with methanol and dried to give the ditartrate of the title compound, mp. 170-178 °C. Yield of the salt formation : 51.9 %.

The starting 4-[3-(4-formyl-1-piperaziny)propylamino]benzyl-cyanide was prepared as follows :

#### Step a)

##### 1-Formyl-4-(3-chloropropyl)piperazine

A mixture of 1-formylpiperazine (5.7 g, 50 mmol), 1-bromo- 3-chloropropane (7.2 ml, 11.8 g, 75 mmol) and chlorobenzene (30 ml) was stirred at 100-105 °C for 3 hours. After cooling the separated 1-formylpiperazine hydrochloride (4.58 g, yield : 94.4 %) was filtered off and the filtrate concentrated. The residue was chromatographed on a silica gel column eluting with a 8:2 mixture of ethyl acetate and methanol to afford 2.46 g of the oily title compound, yield : 51.6 %.

#### Step b)

##### 4-[3-(4-Formyl-1-piperaziny)propylamino]benzylcyanide

A mixture of 1-formyl-4-(3-chloropropyl)piperazine (1.0 g, 5.2 mmol) prepared according to step a) above,

4-aminobenzyl-cyanide (0.66 g, 5 mmol) and sodium iodide (0.15 g, 1 mmol) was heated at 100-105 °C for 2 hours. After cooling the mixture was dissolved in 40 ml of water and treated with decolorizing carbon. The filtered solution was made alkaline with 2 N aqueous NaOH and extracted with chloroform (3 x 20 ml). The organic extracts were washed with water, dried over MgSO<sub>4</sub> and concentrated. The residue was chromatographed on a silica gel column eluting with a 2:1 mixture of ethyl acetate and methanol to give the title compound. Yield : 0.55 g, 38.5 %. Mp. after trituration with ether : 85-87 °C.

#### Example 57

##### 1-(1-Adamantyl)-4-(4,7-diamino-6-phenyl-2-pteridiny)l)piperazine

#### Step a)

##### 1-(1-Adamantyl)-4-amidinopiperazine hydroiodide

The title compound was prepared as described for 1-formylpiperazine in Example 1 of the published European patent application No. 39,190, starting with 1-(1-adamantyl) piperazine and S-methyl-isothiurea hydroiodide, mp. 278-280 °C, yield : 72.3 %.

#### Step b)

##### Isonitrosomalonitrile salt of 1-(1-adamantyl)-4-amidinopiperazine

A solution of sodium nitrite (0.74 g, 10.5 mmol) in water (1 ml) was added dropwise at 0-5 °C to a mixture of malonitrile (0.66 g, 10 mmol), water (1.2 ml) and acetic acid (0.7 ml) and the mixture was stirred first at the same temperature for 2 hours and then at room temperature for further 3 hours. Thereafter the reaction mixture was heated to 50 °C and a mixture of the hydroiodide prepared according to step a) above (3.12 g, 80 mmol) in methanol (6 ml), made alkaline with a 2 N ethanolic NaOEt solution was added. The obtained mixture was stirred at 80-85 °C for 2 hours, the insolubles were filtered off while hot, and the filtrate was concentrated. Trituration of the residue with water afforded 2.40 g of the crude title product, yield : 83.9 %. This crude product was dissolved in acetone, the insolubles were filtered off and the filtrate was concentrated to dryness to give the title compound in pure state, mp. 182-186 °C.

#### Step c)

##### 1-(1-Adamantyl)-4-(4,7-diamino-6-phenyl-2-pteridiny)l)piperazine

To a solution of the salt prepared as described in step b) above (0.50 g, 1.4 mmol) in 2-ethoxyethanol (7 ml) potassium carbonate (0.13 g, 0.9 mmol) was added and the mixture was heated under reflux for 90 minutes. After cooling to about 60 °C NaOH (0.08 g, 2 mmol) was added followed by the dropwise addition of benzylcyanide (0.25 ml, 2.2 mmol) in 2-ethoxyethanol (2 ml) at the same temperature. The mixture was stirred at 80 °C for 2 hours, cooled and diluted with 50 ml of water. The obtained precipitate was collected, washed with water and acetone to give the title compound (0.37 g), yield : 57.8 %, mp. 293-297 °C (dec.).

The above product was converted to its hydrochloride by using an ethyl acetate solution of anhydrous HCl, mp. >231 °C (dec.).

#### Example 58

##### 1-(4,7-Diamino-6-phenyl-2-pteridiny)l)piperazine

#### Step a)

##### 1-(Tert-butoxycarbonyl)-4-amidinopiperazine hydroiodide

The title compound was prepared as described for 1-formylpiperazine in Example 1 of the published European patent application No. 39,190, starting with 1-(1-tert-butoxycarbonyl)-piperazine and S-methyl-isothiurea hydroiodide, mp. 180-182 °C, yield : 66.3 %.

#### Step b)

##### Isonitrosomalonitrile salt of 1-(tert-butoxycarbonyl)-4-amidino-piperazine

The title compound was prepared by following the procedure described in step b) of Example 57, starting

with the hydroiodide obtained according to step a) above, yield : 85.5 %, mp. 155-162 °C.

Step c)

5 1-(Tert-butoxycarbonyl)-4-(4,7-diamino-6-phenyl-2-pteridiny)-piperazine

The title compound was prepared by following the procedure described in step c) of Example 57, starting with the salt obtained according to step b) above, yield : 40 %, mp. 240-242 °C.

Step d)

10

1-(4,7-Diamino-6-phenyl-2-pteridiny)piperazine

A mixture of the protected compound prepared according to step c) above (3.8 g, 9 mmol) and 97 % formic acid (20 ml) was stirred at room temperature for 5 hours. The mixture was then poured into 200 ml of water and the pH was adjusted to 10 with 10 N NaOH. The separated solids were collected, dried and recrystallized from acetonitrile to afford the title compound (1.63 g), yield :  
15 56.2 %, mp. 244-247 °C.

The above product was converted to its hydrochloride by using an ethyl acetate solution of anhydrous HCl, mp. 233-236 °C.

20 Example 59

1-(2,7-Diamino-6-phenyl-4-pteridiny)piperazine

Step a)

25

1-(Tert-butoxycarbonyl)-4-(2,6-diamino-4-pyrimidiny) piperazine

A mixture of 2, 6-diamino-4-chloropyrimidine (2.88 g, 20 mmol) and 1-(tert-butoxycarbonyl)piperazine (5.6 g, 30 mmol) in chlorobenzene (30 ml) was stirred under reflux for 3 hours. After cooling the formed precipitate was collected and stirred with aqueous 1 N NaOH (63 ml) at room temperature for 15 minutes. The solids were  
30 collected, washed with water and dried, yield : 90.4 %, mp. 176-179 °C.

Step b)

1-(Tert-butoxycarbonyl)-4-(2,6-diamino-5-nitroso-4-pyrimidiny)-piperazine

35

A solution of sodium nitrite (4.24 g, 64.6 mmol) in water (43 ml) was added dropwise under 10 °C to a mixture of the product obtained according to step a) above (18.1 g, 64.6 mmol), and acetic acid (180 ml). The mixture was stirred for one hour and the precipitate was collected. This product was stirred with an aqueous 10 % solution of potassium carbonate (230 ml) at room temperature for one hour. The formed pink solids were collected, washed with water and dried at 100 °C, yield : 94.8 %, mp. 235-240 °C (dec.).

40

Step c)

1-(Tert-butoxycarbonyl)-4-(2,7-diamino-6-phenyl-4-pteridiny)-piperazine

45

The title compound was prepared by reaction of the product obtained as described in step b) above with benzylcyanide, following the procedure of Example 37 with the difference that instead of sodium-(2-ethoxyethoxide) NaOH was used as a base. Mp. 245-246 °C, yield : 54.7 %.

Step d)

50

1-(2,7-Diamino-6-phenyl-4-pteridiny)piperazine

By following Method B) of Example 50 deprotection of the compound obtained according to step c) above the title compound was obtained in a yield of 83.0 %, mp.(base) 265-275 °C.

The above product was converted to its ditartrate by following Method A) of Example 50, mp. 150-155 °C.

55 Example 60

1-(2,4,7-Triamino-6-pteridinylcarbonyl)piperazine

Step a)

1-(Tert-butoxycarbonyl)-4-(2-cyanoacetyl)piperazine

A mixture of 1-(tert-butoxycarbonyl)piperazine (37.25 g, 0.20 mol) and ethyl cyanoacetate (22.6 g, 0.20 mol) was heated at 150-155 °C for 3 hours. After cooling the mixture solidified. Trituration with isopropyl ether afforded 24.7 g of the title compound, mp. 143-145 °C, yield : 48.8 %.

Step b)

1-(Tert-butoxycarbonyl)-4-(2,4,7-triamino-6-pteridinylicarbonyl)-piperazine

The title compound was prepared by following the procedure described in Example 37, by reaction of the compound obtained according to step a) above with 5-nitroso-2,4,6-triaminopyrimidine. Yield : 59.1 %, mp. 245-250 °C.


Step c)

1-(2,4,7-Triamino-6-pteridinylicarbonyl)piperazine

The protected compound obtained as described in step b) above was stirred with twofold (v/w) trifluoroacetic acid at 5-10 °C for one hour, diluted with tenfold (v/v) methanol and the precipitate was collected. In this manner the bis-trifluoroacetate of the title compound was obtained, mp. 233-238 °C, yield : 69.8 %.

**Claims**

1. Piperazine and homopiperazine derivatives of the general formula (I),



wherein


Lip stands for hydrogen; C<sub>15-20</sub> alkyl; C<sub>10-20</sub> alkanoyl or C<sub>10-20</sub> alkenoyl; trityl optionally substituted by halogen; adamantyl; 1- or 2-naphthyl or oxo-substituted tetrahydronaphthyl; or an amine protective group commonly used e.g. in the peptide chemistry;

A<sup>1</sup> and A<sup>2</sup> are selected independently from the group consisting of a single bond and C<sub>2-3</sub> alkylene optionally substituted by hydroxy or oxo;

n is 1 or 2; and

Het represents


a group of the general formula (a),



wherein


R<sup>1</sup> is amino or 1-pyrrolidinyl;

or a 4-chloro-3-oxo-2,3-dihydro-5-pyridazinyl group of the formula (b);




(b)

or a 4-amino-6,7-dimethoxy-2-quinazolinyl group of the formula (c);




(c)

or a 4,7-diamino-6-phenyl-2-pteridiny group of the formula (d);




(d)

or a 2,7-diamino-6-phenyl-4-pteridiny group of the formula (e);




(e)

or a 2,4,7-triamino-6-pteridiny carbonyl group of the formula (f);



(f)

or a group of the general formula (g);



(g)

wherein

X means oxygen, sulfur or nitrogen optionally substituted by lower alkyl,

with the first proviso that

when Het stands for a group of the general formula (a) and both A<sup>1</sup> and A<sup>2</sup> mean single bonds then

Lip may not be hydrogen;

with the second proviso that

when Lip is different from naphthyloxy or oxo-substituted tetrahydronaphthyloxy then A<sup>1</sup> means a single bond;

with the third proviso that


when Lip represents naphthyloxy or oxo-substituted tetrahydronaphthyloxy then A<sup>1</sup> may not be a single bond, as well as with the fourth proviso that

A<sup>1</sup> and A<sup>2</sup> cannot simultaneously stand for C<sub>2-3</sub> alkylene optionally substituted by hydroxy or oxo, and their salts.

2. A compound of claim 1 selected from the group consisting of 1-(10-undecenyl)-4-[2,6-di(1-pyrrolidinyl)-4-pyrimidinyl]piperazine, 1-[2-hydroxy-3-(2-naphthyloxy)propyl]-4-[2,6-di(1-pyrrolidinyl)-4-pyrimidinyl]homopiperazine, 6-[4-[2-hydroxy-3-(1-piperazinyl)propoxy]phenyl]-2,4,7-triaminopteridine, 6-[4-[N-methyl-N-[2-hydroxy-3-(1-piperazinyl)propyl]amino]phenyl]-2,4,7-triaminopteridine and the salts thereof.

3. A pharmaceutical composition which comprises as active ingredient one or more compounds of claim 1 or 2, or a pharmaceutically acceptable acid addition salt thereof, optionally in admixture with carriers and/or additives commonly used in the pharmaceutical practice.

4. A process for the preparation of the - compounds of the general formula (I), according to claim 1 or 2,



(I)

wherein

Lip stands for hydrogen; C<sub>15-20</sub> alkyl; C<sub>10-20</sub> alkanoyl or C<sub>10-20</sub> alkenoyl; trityl optionally substituted by halogen; adamantyl; 1- or 2-naphthyloxy or oxo-substituted tetrahydronaphthyloxy; or an amine protective group commonly used e.g. in the peptide chemistry;


A<sup>1</sup> and A<sup>2</sup> are selected independently from the group consisting of a single bond and C<sub>2-3</sub> alkylene optionally substituted by hydroxy or oxo;

n is 1 or 2; and

Het represents

a group of the general formula (a),






(a)


wherein

R¹ is amino or 1-pyrrolidinyl;  
or a 4-chloro-3-oxo-2,3-dihydro-5-pyridazinyl group of the formula (b);




(b)

or a 4-amino-6,7-dimethoxy-2-quinazolinyl group of the formula (c);




(c)

or a 4,7-diamino-6-phenyl-2-pteridiny group of the formula (d);




(d)

or a 2,7-diamino-6-phenyl-4-pteridiny group of the formula (e);




(e)

or a 2,4,7-triamino-6-pteridiny carbonyl group of the formula (f);



(f)

or a group of the general formula (g);



(g)

wherein

X means oxygen, sulfur or nitrogen optionally substituted by lower alkyl,

with the first proviso that

when Het stands for a group of the general formula (a) and both A<sup>1</sup> and A<sup>2</sup> mean single bonds then

Lip may not be hydrogen;

with the second proviso that

when Lip is different from naphthyloxy or oxo-substituted tetrahydronaphthyloxy then A<sup>1</sup> means a single bond;

with the third proviso that

when Lip represents naphthyloxy or oxo-substituted tetrahydronaphthyloxy then A<sup>1</sup> may not be a single bond,

as well as with the fourth proviso that

A<sup>1</sup> and A<sup>2</sup> cannot simultaneously stand for C<sub>2-3</sub> alkylene optionally substituted by hydroxy or oxo, and the pharmaceutically acceptable salts thereof, **characterized** in that

a) for preparing compounds of the general formula (I), wherein

Lip is as defined in claim 1, with the proviso that it may not be hydrogen or an amine protective group;

A<sup>1</sup> is as defined in claim 1, with the proviso that when Lip stands for naphthyloxy or oxo-substituted tetrahydronaphthyloxy then it may not be a single bond; and

n, A<sup>2</sup> and Het are as defined in claim 1,

a compound of the general formula (II),




wherein

Lip and A<sup>1</sup> are as defined above and

L<sup>1</sup> is a leaving group,

is reacted with a compound of the general formula (III),




(III)

wherein


n, A<sup>2</sup> and Het are as defined above; or

b) for preparing compounds of the general formula (I), wherein

Lip means naphthyloxy or oxo-substituted tetrahydronaphthyloxy;  
 A<sup>1</sup> stands for 1,3-propylene substituted by hydroxy; and  
 n, A<sup>2</sup> and Het are as defined in claim 1,  
 a compound of the general formula (IV),




wherein  
 Lip is as defined above,  
 is reacted with a compound of the general formula (III),



25


wherein  
 n, A<sup>2</sup> and Het are as defined above; or  
 c) for preparing compounds of the general formula (I), wherein  
 Lip is as defined in claim 1, with the proviso that it may not be hydrogen;  
 30 A<sup>1</sup> is as defined in claim 1, with the proviso that when Lip stands for naphthyloxy or oxo-substituted tetrahydronaphthyloxy then A<sup>1</sup> may not be a single bond; and with the other proviso that when Lip stands for an amine protective group then A<sup>1</sup> is a single bond; and  
 n, A<sup>2</sup> and Het are as defined in claim 1,  
 a compound of the general formula (V),



wherein  
 Lip, A<sup>1</sup> and n are as defined above,  
 45 is reacted with a compound of the general formula (VI),  

$$\text{L}^2\text{-A}^2\text{-Het}$$
 (VI)

wherein  
 A<sup>2</sup> and Het are as defined above, and  
 50 L<sup>2</sup> stands for a leaving group; or  
 d) for preparing compounds of the general formula (I), wherein  
 Lip means naphthyloxy or oxo-substituted tetrahydronaphthyloxy;  
 A<sup>1</sup> is as defined in claim 1, with the proviso that it may not be a single bond; and  
 n, A<sup>2</sup> and Het are as defined in claim 1,  
 55 a compound of the general formula (VII),



wherein

A<sup>1</sup>, n, A<sup>2</sup> and Het are as defined above, and

L<sup>1</sup> stands for a leaving group,

is reacted with a compound of the general formula Lip-H,

wherein


Lip is as defined above; or

e) for preparing compounds of the general formula (I), wherein

Lip is as defined in claim 1, with the proviso that it may not be naphthyloxy or oxo-substituted tetrahydronaphthyloxy;

A<sup>1</sup> is a single bond;

Het stands for a group of the general formula (g),




(g)

wherein

X is as defined in claim 1; and

n and A<sup>2</sup> are as defined above,

a compound of the general formula (VIII),




(VIII)

wherein

Lip is as defined above, with the proviso that it may not be hydrogen, naphthyloxy or oxo-substituted tetrahydronaphthyloxy; and

n, X and A<sup>2</sup> are as defined above,

is reacted with 5-nitroso-2,4,6-triaminopyrimidine of the formula (IX),



(IX)


and in the case when Lip stands for an amine protective group, this protective group is removed from the compound thus obtained; or

f) for preparing compounds of the general formula (I), wherein

Lip is as defined in claim 1, with the proviso that it may not be naphthyloxy or oxo-substituted tetrahydronaphthyloxy;


both A<sup>1</sup> and A<sup>2</sup> are single bonds;

Het stands for a group of the formula (d);



(d)

and n is as defined in claim 1,  
a compound of the general formula (X),



(X)

wherein

Lip is as defined above, with the proviso that it may not be hydrogen, naphthyloxy or oxo-substituted tetrahydronaphthyloxy; and

n is as defined above,


is reacted with benzyl cyanide and in the case when Lip stands for an amine protective group, this protective group is removed from the product thus obtained; or

g) for preparing compounds of the general formula (I), wherein

Lip is as defined in claim 1, with the proviso that it may not be naphthyloxy or oxo-substituted tetrahydronaphthyloxy;


both A<sup>1</sup> and A<sup>2</sup> are single bonds;

Het stands for a group of the formula (e);



(e)

and n is as defined in claim 1,  
a compound of the general formula (XI),



15 wherein

Lip is as defined above, with the proviso that it may not be hydrogen, naphthyloxy or oxo-substituted tetrahydronaphthyloxy, and

n is as defined above,


20 is reacted with benzyl cyanide and in the case, when Lip stands for an amine protective group, this protective group is removed from the product obtained; or

h) for preparing compounds of the general formula (I), wherein


Lip is as defined in claim 1, with the proviso that it may not be naphthyloxy or oxo-substituted tetrahydronaphthyloxy;

25 both A<sup>1</sup> and A<sup>2</sup> are single bonds;

Het stands for a group of the formula (f);



and n is as defined in claim 1,  
a compound of the general formula (XII),




wherein

Lip is as defined above, with the proviso that it may not be hydrogen, naphthyloxy or oxo-substituted tetrahydronaphthyloxy, and

50 n is as defined above,

is reacted with 5-nitroso-2,4,6-triaminopyrimidine of the formula (IX)



(IX)

and in the case, when Lip stands for an amine protective group, this protective group is removed from the product thus obtained,  
and, if desired, the compound of the general formula (I) prepared by any of the above processes a) - h) is converted to its acid addition salt.

5. A process for preparing a pharmaceutical composition which comprises mixing as active ingredient one or more compounds of claim 1 or 2, or as prepared in claim 4, or a pharmaceutically acceptable acid addition thereof, with carriers and/or additives commonly used in the pharmaceutical practice.
6. Use of the compounds of claim 1 or 2 or the pharmaceutically acceptable salts thereof for the preparation of medicaments for the treatment of patients suffering from diseases and conditions being in direct or indirect connection with pathological peroxidation processes occurring in the living organism, particularly for the treatment of prevention of diseases and conditions where the inhibition of lipid peroxidation is desirable.